

## Review article

# Advancements of 3D bioprinting in regenerative medicine: Exploring cell sources for organ fabrication

Yue Ma<sup>1</sup>, Bo Deng<sup>1</sup>, Runbang He, Pengyu Huang<sup>\*</sup>

State Key Laboratory of Advanced Medical Materials and Devices, Engineering Research Center of Pulmonary and Critical Care Medicine Technology and Device (Ministry of Education), Institute of Biomedical Engineering, Tianjin Institutes of Health Science, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, 300192, China

## ARTICLE INFO

## Keywords:

3D bioprinting  
Seed cells  
Bioink materials  
Cell lines  
Stem cells  
Primary cells

## ABSTRACT

3D bioprinting has unlocked new possibilities for generating complex and functional tissues and organs. However, one of the greatest challenges lies in selecting the appropriate seed cells for constructing fully functional 3D artificial organs. Currently, there are no cell sources available that can fulfill all requirements of 3D bioprinting technologies, and each cell source possesses unique characteristics suitable for specific applications. In this review, we explore the impact of different 3D bioprinting technologies and bioink materials on seed cells, providing a comprehensive overview of the current landscape of cell sources that have been used or hold potential in 3D bioprinting. We also summarized key points to guide the selection of seed cells for 3D bioprinting. Moreover, we offer insights into the prospects of seed cell sources in 3D bioprinted organs, highlighting their potential to revolutionize the fields of tissue engineering and regenerative medicine.

## 1. Introduction

3D bioprinting is an emerging technology that enables the precise layer-by-layer deposition of bioink, a specialized material consisting of living cells, biomaterials, and bioactive molecules [1–6]. This advanced technique allows for the fabrication of complex and functional tissues or organs. The implications of 3D bioprinting are vast, with the potential to generate tailored and functional tissues for diverse applications, including regenerative medicine [7–9], drug discovery [10–13], and toxicology testing [14,15]. However, there are still several challenges that need to be overcome to unlock the full potential of 3D bioprinted tissues and organs.

Regardless of the rapid advancements in additive manufacturing technologies, obtaining suitable seed cells persists in the pursuit of creating fully functional organs through 3D bioprinting [16–18]. Seed cells play an essential role in 3D bioprinting technology since cells are the fundamental units of life. High quality cells are indispensable for generating applicable 3D bioprinted tissues and organs. An ideal cell source possesses several key characteristics.

1. **Printability:** The cells should demonstrate the ability to withstand the rigorous printing process, including shear stress, pressure, and temperature variations, without compromising their viability or functionality. Although suitable bioink materials could help to increase the printability of cells, it is still important for cells utilized for the generation of organs and tissues.

<sup>\*</sup> Corresponding author.

E-mail address: [huangpengyu@yeah.net](mailto:huangpengyu@yeah.net) (P. Huang).

<sup>1</sup> These authors contribute equally.

2. Proliferation: For organ and tissue fabrication, cells need to possess a proliferation capacity in order to expand to the required cell number and adequately populate the 3D bioprinted tissue. However, it is also important to have control over the proliferation of the seed cells. Excessive proliferation could result in hyperplasia which can disrupt the structure and function of 3D bioprinted tissues.
3. Functionality: The cells should either possess functional attributes or have the capability to differentiate into mature functional cells, thereby establishing the desired functionality of the 3D bioprinted organs.
4. Safety: When constructing transplantable normal tissues for therapeutic purposes, it is crucial to use cells with a normal karyotype, non-tumorigenic properties, and devoid of phycological toxicity. Immunological rejection induced by allogeneic or heterogeneous cells is also a serious problem, which should be carefully considered.
5. Economy: The construction of large-scale organs necessitates a substantial number of seed cells. Therefore, the cost-effective large-scale expansion of seed cells is crucial for the applications of 3D bioprinted organs.
6. Self-assembly ability: The microstructure of 3D bioprinted tissues plays a crucial role in achieving full functionalization. The microstructure is primarily formed through the natural self-assembly and organization of cells, which cannot be precisely designed using the current resolution capabilities of 3D bioprinting techniques. The vessel networks of 3D bioprinting vascular tissues mainly relied on the cells [19,20].

An appropriate cell source is key for the successful development of fully functional 3D bioprinted organs. By meticulously selecting seed cells that possess essential characteristics, including printability, proliferation, functionality, safety, economic feasibility, and self-assembly ability, researchers can overcome a significant hurdle in achieving the desired microstructure and multi-functionality of 3D bioprinted tissues and organs [21,22]. In this review, we explored the impact of various 3D bioprinting technologies and bioink materials on seed cells and provided a comprehensive overview of the currently available options for cell sources in 3D bioprinting. Furthermore, we offer insights into the prospects of seed cells for 3D bioprinted organs, highlighting their potential to revolutionize tissue engineering and regenerative medicine.

## 2. Cell requirements in different 3D bioprinting techniques

In recent years, significant advancements have been made in 3D-bioprinting techniques, revolutionizing the field of bioartificial organ construction. 3D bioprinting involves the precise deposition of bioinks composed of living cells and biomaterials, enabling the fabrication of complex tissue structures [23–25]. However, it is important to note that different bioprinting technologies possess unique characteristics, resulting in distinct requirements for seed cells (Table 1).


Extrusion-based bioprinting has gained widespread popularity as a versatile and straightforward 3D-bioprinting technique, capable of creating stable structures [26–28]. This strategy involves the controlled ejection of bioinks from nozzles, which are subsequently cured and stacked layer by layer on the printing plane to build a predefined 3D construct (Fig. 1a) [29,30]. Notably, extrusion-based bioprinting offers a broader selection of bioinks compared to other techniques, facilitating the achievement of high-cell-density printing [31]. However, the pressure and shear stress during the extrusion process could damage the cells. Additionally, the temperature fluctuations or UV stimulation often used for the solidification of the bioink can impose further stress on the cells [32–34]. Therefore, by cooperating with bioinks, cells used in this approach must possess suitable size, shape, and viscosity to be ejected as droplets without compromising their viability or functionality. They should also be capable of withstanding the polymerization process of bioink materials [31,35].

Inkjet bioprinting offers a notable advantage in the precise delivery of biological inks to specific locations according to a determined scheme, allowing for the creation of multifunctional bionic structures while avoiding disruption to existing constructs (Fig. 1b) [36]. This technique enables control of ink droplet sizes as small as picoliters, making it feasible to fabricate artificial tissues and organs at the microscopic scale [37,38]. While inkjet bioprinting is capable of achieving microstructures with small ejected liquid droplets, it can also be utilized for printing large-sized tissues. However, the successful printing of large tissues requires a substantial number of seed cells and bioink [39]. Moreover, for inkjet bioprinting, cells must meet stringent criteria, including compatibility with the bioink materials and the ability to withstand the jetting process [39,40].

Laser-assisted bioprinting (LAB) is capable of generating high-resolution 3D bioprinted tissues, allowing for precise patterning of individual cells and smaller structures [41]. One distinguishing feature of LAB is the elimination of nozzles for bioink deposition, which reduces the risk of contamination and lowers fabrication costs (Fig. 1c) [42]. Additionally, LAB's high printing frequency makes it suitable for constructing high-resolution structures, such as capillary systems, and its *in situ* capability minimizes the potential for secondary damage to transplant recipients [43,44]. However, it is crucial that the cells used in LAB possess the ability to withstand the

**Table 1**  
Requirements of cell sources of different 3D bioprinting techniques.

Technique	Requirements	Ref.
Extrusion-based bioprinting	Suitable size shape, viscosity Stable viability and functionality	[32–34]
Inkjet bioprinting	Compatibility with bioink materials Jetting process resilience	[39,40]
Laser-assisted bioprinting	Stable viability and functionality Laser resilience	[45,46]
Stereolithography bioprinting	Compatibility with light-sensitive materials Light exposure resilience	[50]



**Fig. 1.** Representative 3D bioprinting techniques. (A) Extrusion-based bioprinting; (B) Inkjet bioprinting; (C) Laser-assisted bioprinting; (D) Stereolithography bioprinting.

laser energy applied during the printing process. It is also important to note that the laser-induced transfer process can potentially disrupt cell structure [45,46]. The influence of laser and UV on the DNA of cells should also be considered when applying the laser-assisted bioprinting technique [47].

Stereolithography bioprinting utilizes digital micromirror arrays to control the light intensity in each pixel, enabling the polymerization of light-sensitive polymer materials (Fig. 1d) [48,49]. This technique provides several advantages such as high printing efficiency, exceptional resolution, and a stable model framework, making it well-suited for fabricating large tissues and organs. For this strategy, cells must be compatible with the light-sensitive polymer materials, capable of enduring the polymerization conditions induced by light exposure, and able to maintain their viability, functionality, and structural integrity throughout the printing and post-printing stages [50].

While 3D bioprinting technology holds promise in alleviating the scarcity of organs for transplantation, challenges persist in the preoperative fabrication, *in vitro* cultivation, and transplantation processes, posing considerable risks and limitations [51,52]. The emerging *in situ* 3D bioprinting technology, which allows direct organ printing at the transplant site, shows the potential to mitigate these issues to some extent. Currently, various studies have explored the application of *in situ* 3D bioprinting in skin repair and bone reconstruction. The use of *in situ* 3D bioprinted skin [53] and bones [54] has demonstrated its ability to expedite wound healing and reduce immune rejection reactions. Beyond skin and bones, *in situ*, 3D bioprinting technology proves highly effective in specific applications within oral medicine and certain ophthalmic implants [55,56]. With the continual enhancement of 3D printing precision, it is anticipated that *in situ* 3D bioprinting technology will find an even broader range of applications.

Novel bioprinting techniques, such as acoustic bioprinting [57–59], magnetic bioprinting [60–62], electrohydrodynamic bioprinting [63,64], and other innovative approaches, are emerging to address the constraints of conventional methods and open up new possibilities in the creation of complex tissue. A significant focus of these advancements is the integration of precise control

mechanisms to improve cell viability and functionality when fabricating intricate tissue architectures.

### 3. Influences of bioink materials on cells

Bioink, a combination of seed cells and bioprinting materials, plays a core role in achieving high-density cell distribution within bioprinted structures while maintaining their biological function throughout the 3D-bioprinting process [65,66]. Serving as a delivery and support system, bioink materials ensure the transportation and sustenance of seed cells during bioprinting. Moreover, bioink materials regulate biocompatibility, mechanical properties, and rheological characteristics of the bioprinting structure [67–69]. Additionally, bioink materials create a supportive microenvironment for the cells, which is essential for achieving functional and physiologically relevant 3D-bioprinting tissues and organs. An ideal bioink material should be able to mimic the intricate extracellular matrix (ECM) of the target tissue or organ while exhibiting appropriate rheological properties that enable extrusion or deposition through the bioprinting system [70–72].

The utilization of natural materials in 3D bioprinting has garnered significant attention due to their exceptional biocompatibility, biodegradability, and potential to enhance cell survival, function, adhesion, and self-organization [73–75]. Extensive research and optimization have been conducted on several natural materials, including collagen, gelatin, alginate, hyaluronic acid, and chitosan, to develop them as bioink materials for 3D bioprinting [76–84]. Acellular tissue matrix, which contains mixed tissue-specific ECM components, is often incorporated into the bioink materials to provide a tissue-specific environment with signaling and mechanical properties [85,86]. Natural materials generally exhibit low immunogenicity, and reduce the risk of causing adverse reactions [68,87]. Furthermore, their ability to undergo biological degradation over time is crucial for establishing cell-cell interactions and ECM remodeling during the functionalization of 3D bioprinted organs [88,89]. Natural materials also offer the advantage of incorporating bioactive molecules, growth factors, and cytokines into their structures, further enhancing the microenvironment for seed cells (Fig. 2). However, the relatively limited options of natural materials cannot meet the increasing demand for diverse mechanical properties and precise manufacturing controls [90–92].

Synthetic materials, typically derived from non-biological sources through chemical synthesis or manufacturing processes, offer flexibility in tailoring their mechanical properties to adapt different 3D bioprinting approaches [93]. These materials can be engineered to possess specific characteristics such as stiffness, toughness, elasticity, and crosslinking modes [87]. Due to their superior mechanical properties and consistent quality, synthetic materials find wide application in the 3D bioprinting of large-scale tissues and organs [94,95] (Fig. 2). Among the synthetic polymers used in 3D bioprinting, polycaprolactone (PCL) stands out for its excellent biocompatibility and ease of shaping. However, it exhibits limited capability in effectively encapsulating cells. With a low melting




Fig. 2. Advantages of different bioink materials for 3D bioprinting.

point, PCL is suitable for extrusion-based 3D bioprinting and finds applications in printing scaffolds for bone, cartilage, and vascular tissue engineering [96–98]. Polyethylene glycol (PEG), known for its hydrophilicity and cell-friendly nature, allows for cell attachment and proliferation. PEG-based bioink materials can be customized to exhibit specific mechanical properties and degradation rates, making them suitable for vascular, cartilage, and heart bioprinting, as well as for use in bioprinted organ scaffolds [99–101]. Poly (lactic-co-glycolic acid) (PLGA), on the other hand, has been utilized in scaffold development for nerve tissue regeneration [102–105]. Synthetic materials used in 3D bioprinting must demonstrate high biocompatibility, low immunogenicity, and good tolerance by cells and tissues [106–108].

Achieving the multifunctionality of complex tissues and organs using a single type of bioink poses several challenges [109–111]. Simply increasing the concentration of bioinks to enhance the mechanical properties of bioprinting structures lacks the ability to selectively couple small molecules or dynamically alter the printed structures [112–114]. To address these limitations and enhance the specificity and controllability of bioinks, the utilization of chemically modified and environmentally responsive materials holds promise. By incorporating such materials, it becomes possible to improve the performance of bioinks, allowing for precise modulation and responsiveness to specific cellular environments and stimuli [115–119].

#### 4. Cell sources for 3D bioprinting

Cells are the fundamental building blocks for 3D bioprinted tissues and organs [120,121]. Despite the explosive development of various approaches to generate stem cells or functional cells for generative medicine purposes, many cell types are currently not suitable for 3D bioprinting due to their fragility during the printing process, limited proliferation ability, inability to adapt to the bioink materials, insufficient functionality, tumorigenic risk, costly culture system, and other limitations [28,122]. In this context, we provide a summary of commonly used cell types as well as potential cell types that show promise for use in 3D bioprinting applications.

##### 4.1. Cell lines

Cell lines are populations of cells that maintain stable phenotypes and functions over an extended period of time. They are frequently employed as models in the development of 3D bioprinting technologies, especially because primary cell types are usually difficult to maintain and expand *in vitro*. There are many advantages of cell lines, such as easy handling and cost-effectiveness [123, 124]. Their culture does not require complex conditions and is robust against environmental changes and mechanical stresses. Various cell lines have made significant contributions to the establishment and optimization of 3D bioprinting technologies (Table 2) [125–132]. For instance, beta-TC60, an immortalized mouse cell line capable of insulin secretion was utilized in the initial inkjet bioprinting experiments [133]. Human umbilical vein endothelial cell lines, smooth muscle cell lines, and skin fibroblast cell lines have been widely employed in the development of bioprinted vascular systems [134,135]. HepaRG cells, an immortalized hepatic cell line that maintains many hepatic functions, were utilized in the construction of a transplantable 3D bioprinted liver. When transplanted into a liver injury mouse model, this 3D bioprinted bioartificial liver persisted for over 8 weeks *in vivo* and demonstrated therapeutic effect [136].

Numerous cell lines are derived directly from tumors, while others are generated from primary cells of normal tissues by disabling cell cycle arrest or senescence genes such as p53, Rb, and p16 [137,138]. This can be achieved through spontaneous mutations, shRNA, gene editing, or the overexpression of Simian Vacuolating Virus 40 large T antigen [139–142]. Therefore, cell lines are capable of

**Table 2**  
Cell lines used in 3D bioprinting.

Cell lines	Bioprinting techniques	Bioink materials	Tissues or Organs	Ref.	
MCF-7, MDA-MB-468, MCF-12A	Extrusion-based	ECM	Mammary organoids and tumoroids	[125]	<b>Advantages:</b> Diverse sourcing options Cost-effectiveness Easy cultivation
Glioblastoma stem cells	Digital light processing (DLP)-based	Photocrosslinkable native ECM derivatives	Biomimetic 3D cancer microenvironment	[126]	
Mouse myoblast cells (C2C12s)	Extrusion-based	Oxidized alginate-gelatin (ADA-GEL) hydrogel	Muscle tissue	[127]	Stable proliferation Excellent homogeneity
Huh7 & HepaRG	Extrusion-based	Fibrinogen, gelatin & alginate	Skeletal muscle-like bundles	[128]	<b>Disadvantages:</b> Carcinogenic risk Lack certain organ-specific functions
HUVECs	Extrusion-based	GelMA	Bone-like tissue with vascular lumen	[129]	
Valvular interstitial cells (VICs)	Extrusion-based	Alginate & gelatin	Aortic valves tissue	[130]	
Caco-2 cells	Extrusion-based	GelMA	Intestinal villi and hair follicles	[131]	
MCF-7 & BT-474	Extrusion-based	Mammocult & Matrigel	Breast adenocarcinoma tissue	[132]	
Beta-TC60	Inkjet	Alginate hydrogel	Single-cell based microparticles	[133]	
HepaRG	Extrusion-based	Gelatin & sodium alginate	Liver	[136]	
HEK 293FT	Extrusion-based	Gelatin & sodium alginate	Kidney tissue models	[147]	
Huh7 & HepaRG	Extrusion-based	Gelatin methacryloyl (GelMA)	Liver model	[149]	
HepG2	Drop-on-Demand (DoD)	Agarose, gelatin & collagen	Functional liver carcinoma model	[150]	



continuous proliferation, making it easy and cost-effective to produce a large quantity of cells. However, the high proliferative capacity of cell lines may not always be advantageous for 3D bioprinting. While many cell lines exhibit contact inhibition and cease proliferation after population of the 3D bioprinted constructs, others, particularly those derived from tumors such as HepG2 cells, can continue proliferating and give rise to neoplasms. Therefore, it is crucial for cells to proliferate and populate the 3D bioprinted construct appropriately, with proliferation ceasing after the formation of functional structures.

Another notable advantage of cell lines is their homogeneity [143]. Cell lines have the ability to undergo clonal expansion, generating populations of cells with identical genetic profiles [144]. This uniformity allows for the fabrication of homogeneous tissues and organs, ensuring consistent and reliable outcomes in the printed constructs. Moreover, the utilization of homogenous cells offers stability and high reproducibility when developing new 3D bioprinting technologies.

However, when it comes to constructing transplantable 3D bioprinted tissues and organs for therapeutic purposes, there are certain challenges to consider. Many cell lines exhibit abnormal karyotypes or carry mutations in oncogenes and tumor suppressor genes, increasing the risk of tumor formation [145,146]. For example, the human HEK 293 cell line, used in the construction of 3D kidney models, is a hypotriploid cell line with 64 chromosomes [147]. A karyology analysis of the human umbilical vein endothelial cells (HUVEC) cell line (CRL-1730) provided by the American Type Culture Collection (ATCC) showed that 87.8 % of the cells are hypodiploid or polyploid [148].

Another disadvantage of cell lines is their inability to fully replicate the mature and specialized functions of their *in vivo* counterparts. Although many cell lines retain some marker genes associated with their origin cell types, they often lack or have significantly reduced functional characteristics. For instance, HepG2 cells, a commonly used hepatoblastoma cell line that has been used for constructing a 3D liver-like model, express the *ALBUMIN* gene, a common hepatic marker, but they exhibit defects in drug metabolism, urea metabolism, coagulation system, and more [149,150]. Thus, it is nearly impossible to reconstruct a fully functional artificial liver based on HepG2 cells. Consequently, it is crucial to explore safer cell sources that are capable of generating mature functional cells with controlled proliferation.

#### 4.2. Stem cells

Stem cells, possessing the remarkable ability to self-renew and differentiate into various cell types, offer tremendous potential as cell sources for 3D bioprinted tissues and organs (Table 3) [151–159]. In recent years, stem cells and their derivatives have already demonstrated remarkable advancements in clinical applications, particularly in treating hematological disorders, cardiovascular diseases, bone injuries, skin wounds, and more [160–162]. These developments highlight the promising future of stem cells in regenerative medicine. Particularly, the rapid progress of Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which can give rise to virtually any cell type in the body, has led to an increasing number of available cell types for research and applications [163,164].

One of the most discussed advantages of stem cells is their theoretically unlimited proliferation capability, which holds the potential for generating an unlimited number of functional cells. This feature becomes particularly valuable when it is challenging to culture their counterpart cells *in vitro*. In recent years, numerous technologies have been developed to induce the differentiation of ESCs and iPSCs into various functional cell types, such as neurons, cardiomyocytes, hepatocytes,  $\beta$  cells, muscle cells, and endothelial

**Table 3**  
Stem Cells used in 3D bioprinting.

Cell types	Bioprinting techniques	Bioink materials	Tissues or Organs	Ref.	
hiPSC-derived neural progenitor cells	Microfluidics -based	Fibrin-based bioink	Neural tissue	[13]	<b>Advantages:</b> Easy accessibility Pluripotency Strong proliferation Stable genetic
Human Adipogenic Mesenchymal Stem Cell (hADMSCs)	Extrusion-based	Pluronic acid as the sacrificial material and type I collagen	Cardiac Purkinje System	[151]	
iPSCs	Drop-on-demand	Alginate hydrogel	iPS tissue	[152]	<b>Disadvantages:</b> Mature functionality post-differentiation Carcinogenic risk High cultivation costs
	Extrusion-based	Hydroxypropyl chitin (HPCH)	iPS tissue	[153]	
	Extrusion-based	Gelatin	Neural tissue	[166]	
iPSC-derived cardiomyocytes	Extrusion-based	Collagen I and Matrigel	Cardiac	[154]	
iPSC-derived neural cells	Microextrusion-based	Gelatin	Neural tissue	[155]	
iPSCs-derived cardiomyocytes (CMs) and ECs	Extrusion-based	Patient-derived dECM & gelatin	Cardiac tissue	[156]	
iPSC-derived mesenchymal stem cell	Extrusion-based	Alginate & gelatin	Endometrium tissue	[157]	
iPSC-derived neural aggregates	Extrusion-based	Alginate, fibrin & genipin	Neural tissue	[158]	
hiPSCs	Sequential printing in a reversible ink template (SPIRIT)	GelMA, Alginate & Gelatin	Vascular tissue	[159]	
iPS Cells-derived cardiomyocytes and hepatocytes	DLP-based	Decellularized extracellular matrices (dECM)	Myocardium tissue , liver	[165]	
Mouse embryonic stem cells	Extrusion-based	Gelatin & alginate	N/A	[167]	

cells. Many of these protocols have been successfully utilized to produce large quantities of functional cells for constructing 3D hepatic, cardiac, and neural tissues [165–167]. Recently, iPSCs have been effectively differentiated into endothelial cells and retinal pigment epithelial cells, which, when combined with pericytes and fibroblasts, can generate a 3D bioprinting tissue that mimics the outer-blood-retina-barrier in the back of the eye [168].

However, the proliferation capability of stem cells decreases as they undergo differentiation. Once fully differentiated, these cells typically lose their ability to divide and become unable to populate the 3D constructs. To address this challenge, a compromised strategy is to guide the stem cells to differentiate into committed stage or progenitor cells that retain the ability to proliferate. After the initial population of the 3D bioprinting structure, further differentiation and maturation can be induced, allowing for the development of functional and mature tissues and organs.

Another distinct advantage of pluripotent stem cells in 3D bioprinting is the generation of multiple cell types with the same genetic background. This becomes particularly useful in clinical settings where the goal is to construct an artificial organ using cells exclusively sourced from the same individual. With the help of iPSCs, the theoretical possibility of creating a 3D bioprinted organ using a patient's cells arises, thereby addressing the issue of immune rejection. Recently, a proof of principle study has used neural stem cells, endothelium, and neurons derived from the same population of iPSCs to generate patterned neural tissues by 3D bioprinting [169]. However, due to the complex and time-consuming nature of the iPSC generation process, the current focus does not prioritize the production of patient-specific 3D bioprinted organs based on iPSCs.

Before the clinical application of ESC or iPSC-based 3D bioprinting technologies, several safety concerns need to be addressed. These include the risk of genetic and epigenetic abnormalities and the potential tumorigenicity of undifferentiated pluripotent stem cells. In recent years, significant efforts have been dedicated to enhancing the safety. Researchers are working on developing ESC and iPSC strains with normal karyotypes, avoiding tumorigenic mutations, and implementing good manufacturing practices (GMP) during the production process to meet the requirements for clinical applications. The emerging clinical applications of ESC and iPSC-derived cells hold tremendous potential as cell sources for 3D bioprinting tissues or organs with therapeutic purposes [170–175].

In addition to pluripotent stem cells, there are many other stem cells available for use as cell sources in 3D bioprinting, including adult stem cells such as mesenchymal stem cells (MSCs). Among them, MSCs have the potential to differentiate into multiple cell lineages and promote tissue regeneration, which made them widely used in 3D bioprinting technology development and tissue repair research [23,176,177]. These cells are typically obtained by expanding primary cells derived from somatic tissues through *in vitro* culture, and their applications will be discussed in the following sections.

#### 4.3. Cells derived by transdifferentiation

Mammalian cells have demonstrated the ability to undergo transdifferentiation, which offers a new avenue for cell sources in regenerative medicine [178,179]. By overexpressing lineage-specific transcription factors, somatic cells have successfully been converted into neurons, hepatocytes, cardiomyocytes, endothelial cells, and myofibroblasts [180–183]. Transdifferentiation technology provides a simpler and less time-consuming approach to generating patient-specific functional cells, bypassing the pluripotent stage and avoiding associated risks. In recent clinical experiments, hepatocytes generated through transdifferentiation have shown remarkable therapeutic effects in bioartificial liver support systems, offering promising prospects for advanced interventions [184–188].

However, one limitation of transdifferentiated neurons, cardiomyocytes, and hepatocytes, is their limited potential for *in vitro* proliferation. To address this issue approaches such as silencing p19Arf or overexpressing SV40 large T antigen have been used to expand transdifferentiated hepatocytes, although this raises additional safety concerns [184,186]. Another strategy involves generating proliferative neural stem cells or liver stem cells through transdifferentiation [189,190]. Additionally, the relatively low transdifferentiation efficiency has also hindered its applications, though significant efforts have been made to substantially improve the efficiency [191]. Despite several breakthroughs in the applications of transdifferentiation cells, their use in 3D bioprinting is still largely unexplored, representing a fertile ground for further investigation.

#### 4.4. Primary cells

Primary cells derived from adult normal tissues are highly regarded as valuable cell sources due to their excellent safety profile and functional performance [192]. However, their practical application has been hindered by the limited availability of suitable donor sources and the challenges associated with *in vitro* culture and expansion. Freshly isolated primary cells are often delicate and vulnerable to the stresses imposed by temperature, pressure, and shear forces during 3D bioprinting, leading to high mortality rates [192–194].

Nonetheless, significant progress has been made in recent years with continuous *in vitro* expansion and culture techniques for various primary cell types. Hepatocytes, muscle satellite cells, small intestine stem cells, and lung stem cells have seen breakthroughs in large-scale expansion *in vitro* [195–199]. These *in vitro* expanded primary cells demonstrate improved adaptability to the 3D bioprinting process and exhibit relatively higher cell survival rates when subjected to *in vitro* conditioning [192,200]. Furthermore, these cells maintain a normal karyocyte post-expansion and exhibit functional maturity or the ability to differentiate into mature functional cells [201,202]. Notably, they possess enhanced self-assembly capabilities, enabling the formation of intricate microstructures.

The remarkable progress has led to the inclusion of these cells in clinical trials for *in vivo* cell transplantation therapies, underscoring their favorable safety profiles and the potential for smooth translation into clinical applications in the future. This promising development paves the way for their utilization of cutting-edge medical treatments, providing hope for improved patient outcomes and

advancements in regenerative medicine. We summarized the key benefits of utilizing primary cells in 3D bioprinting as follows.

- (1) Better physiological relevance: Primary cells retain the *in vivo* phenotype and function of native tissues, ensuring a closer representation of physiological conditions.
- (2) Tissue-specific functions: Primary cells exhibit tissue-specific functions, making them well-suited for fabricating organ-specific structures and functions, offering a more accurate and specialized tissue model.
- (3) Patient-specific: Primary cells can be sourced directly from a patient's tissue, allowing for the generation of personalized organ constructs that closely mimic the individual's unique biological characteristics. This personalized approach holds immense promise for regenerative medicine applications.
- (4) Better integration: Primary cells possess remarkable integration capabilities within host tissues, minimizing the risk of immune rejection and enhancing the overall functionality of the 3D-bioprinting tissue or organ. This improved integration promotes long-term tissue function and enhances the potential for successful transplantation.

By harnessing the unique characteristics of primary cells, several kinds of primary cells had been utilized in the 3D bioprinting of tissues and organs (Table 4) [176,203–208]. Primary human hepatocytes and hepatocellular carcinoma cells were applied in constructing the liver and liver cancer models [194,209]. Primary fibroblasts and intestinal cells have also been employed in the generation of skin tissues and intestinal models [192,193,210].

Despite these unique strengths of primary cells, several limitations need to be addressed to fully harness their potential [120, 211–214]. Primary cells are difficult to obtain, especially from human tissues, and their isolation and expansion are often time-consuming and labor-intensive. Besides, the heterogeneity of primary cells makes their behavior vary depending on the donor, tissue source, and culture conditions.

Primary cells have a limited lifespan, and their replicative potential decreases with each passage. The differentiation capacity of primary cells can be affected by the culture conditions, resulting in variability in the quality of 3D-bioprinting tissue or organ constructs. The biggest limitation of the usage of primary cells is the ethical concerns, especially for the cells sourced from human tissues, as the collection of tissues may require informed consent and approval from ethical review boards.

The use of primary cells in 3D bioprinting has the potential to revolutionize the field of regenerative medicine. However, to fully harness their potential, limitations such as their limited availability, heterogeneity, and differentiation capacity need to be addressed through the development of standardized isolation and culture protocols [121,215,216].

#### 4.5. Trends and prospects of cell sources

Finding a suitable cell source for 3D bioprinting is a critical decision that greatly influences the success and functionality of generated tissue or organ. Different cell types bring their own set of advantages and limitations to the table (Fig. 3). Understanding these factors and selecting the most suitable cell type for a particular application is paramount in achieving the desired outcome of functional and viable tissue models [216–219].

**Table 4**  
Primary Cells used in 3D bioprinting.

Cell types	Bioprinting techniques	Bioink materials	Tissues or Organs	Ref.	
Human mesenchymal stem cells (hMSCs)	Extrusion-based	Alginate- and silk-based	Smart dual scaffold	[23]	<b>Advantages:</b> High safety Stable functionality Patient-specific
hMSCs	Femtosecond-laser-assisted	Tunicate cellulose nanofibrils & Alginate-based	Cell-laden corneal tissue	[176]	
Human primary dermal fibroblasts	Inkjet	ECM-like BioInk	Soft tissue models	[192]	Excellent <i>in vivo</i> integration capability
Primary normal human fibroblasts (NHF)	Magnetic-based	Collagen	Skin tissue	[193]	<b>Disadvantages:</b> Limited cell sources
Primary human hepatocytes	Extrusion-based	GelMa	Liver	[194]	High cost
Primary Skeletal Muscle Progenitor Cells	Extrusion-based	GelMA	Skeletal muscle	[200]	Weak proliferation ability High heterogeneity
Primary human osteoblasts	Extrusion-based	GelMA	Osteoblasts scaffold	[203]	
Primary human keratocytes	Extrusion-based	Collagen-based	Corneal stromal tissue	[204]	
hMSCs	Extrusion-based	GelMA	Compact macro tissue	[205]	
HUVECs	Extrusion-based	GelMA-Fibrin	Vascular tissue	[206]	
Human umbilical vein & artery cells	Microfluidic bioprinting	Alg/Gel/GelMA	Vascular tissue	[207]	
Human nasoseptal chondrocytes	Extrusion-based	Nanocellulose-alginate	Rounded chondrogenesis	[208]	
Hepatocellular carcinoma (HCC) cells	Extrusion-based	Gelatin & sodium alginate	HCC Model	[209]	
Primary intestinal cells	Extrusion-based	Novogel	Intestinal models	[210]	



It is crucial to carefully consider the advantages and limitations of each cell type to the specific requirements of the tissue or organ being generated. Factors such as printability, proliferation capacity, functionality, safety, and economic considerations should be taken into account during the selection process.

By making informed decisions regarding cell types, researchers can optimize the outcomes of 3D bioprinting, leading to the fabrication of functional and viable tissue models that hold immense potential for various applications, including drug screening, disease modeling, personalized medicine, and regenerative therapies.

**5. Discussion and future perspectives**


The 3D bioprinting technique is experiencing rapid and remarkable advancements, holding the potential for swift application in drug screening and evaluation processes. Researchers have successfully bioprinted vascularized tissues and organs, improving cell survival and functionality [220,221]. Multicellular bioinks that mimic native tissue microenvironments have been developed, enabling the creation of bioprinted constructs resembling native organs [222,223]. These advancements bring us closer to viable organ transplantation alternatives and personalized medicine. While 3D-bioprinting organs for *in vivo* transplantation is still a work in progress, future research will concentrate on overcoming key challenges.

One critical area is vascularization, where the establishment of a functional vascular network capable of connecting with the body’s native blood vessels becomes essential. A multi-level vascular network is needed to ensure the long-term survival and growth of the 3D-bioprinting organ, incorporating smooth muscle and composition of vascular endothelial cells within the blood vessels.

Another crucial step is massification, requiring a substantial quantity of cells. This places greater demands on the *in vitro* expansion culture of cells. Finding ways to reduce the production cost of a significant cell quantity becomes an important consideration.

Ensuring safety is another essential aspect. The production process must avoid immune problems stemming from animal-derived components to safeguard cell safety effectively.

Additionally, achieving functionalization poses a challenge in current 3D bioprinting. The current technology lacks the ability to establish functional connections between cells. Consequently, cells need to self-organize and proliferate to form mature functional microstructures, often necessitating additional *in vitro* culturing of 3D bioprinting organs and further functionalization post-



**Fig. 3.** Advantages of different cell sources available for 3D bioprinting.

transplantation. Furthermore, cell sources for 3D bioprinting require a high level of functionality, prompting exploration of methods to enhance the functional capabilities of cells.

Addressing these challenges will be crucial to advancing the field of 3D bioprinting and realizing the development of functional and transplantable artificial organs. Through ongoing research and innovation, the goal of creating viable, safe, and fully functional 3D-bioprinting organs will come within closer reach.

## 6. Conclusion

3D bioprinting technology holds immense potential for organ fabrication. A crucial challenge in successful 3D bioprinting is the availability of a substantial quantity of cells. Different cell types offer unique advantages and face their limitations. With ongoing advancements in cell isolation and culture technologies, the challenges of cell sources in 3D bioprinting will be overcome, significantly impacting the field of regenerative medicine.

## Ethics approval and consent to participate

An ethics statement is not applicable.

## Funding and acknowledgments

P.H. is funded by the Ministry of Science and Technology of China (MOST; 2019YFA0801501), CAMS Innovation Fund for Medical Sciences (2021-I2M-1-058, 2022-I2M-2-003), Central Public-Interest Scientific Institution Basal Research Fund (2021-RC310-004, 2020-RC310-007, 2023-PT310-05). Tianjin Natural Science Foundation for Distinguished Young Scholars (21JJCQJC00030), Beijing-Tianjin-Hebei Basic Research Cooperation Special Project (22JCZXCJC00200) and NSFC grants (31970687).

## Data availability statement

No data was used for the research described in the article.

## CRediT authorship contribution statement

**Yue Ma:** Writing – review & editing, Writing – original draft. **Bo Deng:** Writing – review & editing, Writing – original draft. **Runbang He:** Writing – review & editing, Writing – original draft. **Pengyu Huang:** Writing – review & editing, Writing – original draft, Supervision, Project administration, Investigation, Funding acquisition.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## References

- [1] K. Jakab, C. Norotte, F. Marga, K. Murphy, G. Vunjak-Novakovic, G. Forgacs, Tissue engineering by self-assembly and bio-printing of living cells, *Biofabrication* 2 (2010) 022001, <https://doi.org/10.1088/1758-5082/2/2/022001>.
- [2] R.A. Agha, A.J. Fowler, T.E. Pidgeon, G. Wellstead, D.P. Orgill, V.S. Group, Protocol for the development of a core outcome set for autologous fat grafting to the breast, *Int. J. Surg.* 31 (2016) 104–106, <https://doi.org/10.1016/j.ijso.2016.05.067>.
- [3] N.A. Sears, D.R. Seshadri, P.S. Dhavalikar, E. Cosgriff-Hernandez, A review of three-dimensional printing in tissue engineering, *Tissue Eng Part B Rev* 22 (2016) 298–310, <https://doi.org/10.1089/ten.TEB.2015.0464>.
- [4] T.A. Mir, M. Nakamura, Three-Dimensional bioprinting: toward the Era of manufacturing human organs as spare parts for healthcare and Medicine<sup>sup>&gt;, *Tissue Eng Part B Rev* 23 (2017) 245–256, <https://doi.org/10.1089/ten.TEB.2016.0398>.
- [5] Z.P. Kacarevic, P.M. Rider, S. Alkildani, S. Retnasingh, R. Smeets, O. Jung, Z. Ivanisevic, M. Barbeck, An introduction to 3D bioprinting: possibilities, challenges and future aspects, *Materials* 11 (2018), <https://doi.org/10.3390/ma11112199>.
- [6] A.C. Dell, G. Wagner, J. Own, J.P. Geibel, 3D bioprinting using hydrogels: cell inks and tissue engineering applications, *Pharmaceutics* 14 (2022), <https://doi.org/10.3390/pharmaceutics14122596>.
- [7] A.I. Cernencu, A.I. Dinu, I.C. Stancu, A. Lungu, H. Iovu, Nanoengineered biomimetic hydrogels: a major advancement to fabricate 3D-printed constructs for regenerative medicine, *Biotechnol. Bioeng.* 119 (2022) 762–783, <https://doi.org/10.1002/bit.28020>.
- [8] W. Aljohani, M.W. Ullah, X. Zhang, G. Yang, Bioprinting and its applications in tissue engineering and regenerative medicine, *Int. J. Biol. Macromol.* 107 (2018) 261–275, <https://doi.org/10.1016/j.ijbiomac.2017.08.171>.
- [9] M. Samandari, A. Mostafavi, J. Quint, A. Memic, A. Tamayol, In situ bioprinting: intraoperative implementation of regenerative medicine, *Trends Biotechnol.* 40 (2022) 1229–1247, <https://doi.org/10.1016/j.tibtech.2022.03.009>.
- [10] S. Bendels, C. Bissantz, B. Fasching, G. Gerebtzoff, W. Guba, M. Kansy, J. Migeon, S. Mohr, J.U. Peters, F. Tillier, et al., Safety screening in early drug discovery: an optimized assay panel, *J. Pharmacol. Toxicol. Methods* 99 (2019) 106609, <https://doi.org/10.1016/j.vascn.2019.106609>.
- [11] B.G. Pavan Kalyan, L. Kumar, 3D printing: applications in tissue engineering, medical devices, and drug delivery, *AAPS PharmSciTech* 23 (2022) 92, <https://doi.org/10.1208/s12249-022-02242-8>.
- [12] E. Ning, G. Turnbull, J. Clarke, F. Picard, P. Riches, M. Vendrell, D. Graham, A.W. Wark, K. Faulds, W. Shu, 3D bioprinting of mature bacterial biofilms for antimicrobial resistance drug testing, *Biofabrication* 11 (2019) 045018, <https://doi.org/10.1088/1758-5090/ab37a0>.
- [13] R. Sharma, I.P.M. Smits, L. De La Vega, C. Lee, S.M. Willerth, 3D bioprinting pluripotent stem cell derived neural tissues using a novel fibrin bioink containing drug releasing microspheres, *Front. Bioeng. Biotechnol.* 8 (2020) 57, <https://doi.org/10.3389/fbioe.2020.00057>.

- [14] M. Gori, S.M. Giannitelli, M. Torre, P. Mozetic, F. Abbruzzese, M. Trombetta, E. Traversa, L. Moroni, A. Rainer, Biofabrication of hepatic constructs by 3D bioprinting of a cell-laden thermogel: an effective tool to assess drug-induced hepatotoxic response, *Adv. Healthcare Mater.* 9 (2020) e2001163, <https://doi.org/10.1002/adhm.202001163>.
- [15] I. Moraleja, D. Esteban-Fernandez, A. Lazaro, B. Humanes, B. Neumann, A. Tejedor, M. Luz Mena, N. Jakubowski, M.M. Gomez-Gomez, Printing metal-spiked inks for LA-ICP-MS bioimaging internal standardization: comparison of the different nephrotoxic behavior of cisplatin, carboplatin, and oxaliplatin, *Anal. Bioanal. Chem.* 408 (2016) 2309–2318, <https://doi.org/10.1007/s00216-016-9327-0>.
- [16] L. Bian, Functional hydrogel bioink, a key challenge of 3D cellular bioprinting, *APL Bioeng.* 4 (2020) 030401, <https://doi.org/10.1063/5.0018548>.
- [17] D. Brezulier, L. Chaigneau, S. Jeanne, R. Lebullenger, The challenge of 3D bioprinting of composite natural polymers PLA/bioglass: trends and benefits in cleft palate surgery, *Biomedicines* 9 (2021), <https://doi.org/10.3390/biomedicines9111553>.
- [18] M. van Daal, M.E. Muntinga, S. Steffens, A. Halsema, P. Verdonk, Sex and gender bias in kidney transplantation: 3D bioprinting as a challenge to personalized medicine, *Womens Health Rep (New Rochelle)* 1 (2020) 218–223, <https://doi.org/10.1089/whr.2020.0047>.
- [19] M. Isik, E. Karakaya, T.S. Arslan, D. Atila, Y.K. Erdogan, Y.E. Arslan, H. Eskizengin, C.C. Eylem, E. Nemutlu, B. Ercan, et al., 3D printing of extracellular matrix-based multicomponent, all-natural, highly elastic, and functional materials towards vascular tissue engineering, *Adv. Healthcare Mater.* (2023) e2203044, <https://doi.org/10.1002/adhm.202203044>.
- [20] P. Wang, Y. Sun, X. Shi, H. Shen, H. Ning, H. Liu, 3D printing of tissue engineering scaffolds: a focus on vascular regeneration, *Biodes Manuf* 4 (2021) 344–378, <https://doi.org/10.1007/s42242-020-00109-0>.
- [21] W.L. Ng, X. Huang, V. Shkolnikov, G.L. Goh, R. Sutorndond, W.Y. Yeong, Controlling droplet impact velocity and droplet volume: key factors to achieving high cell viability in sub-nanoliter droplet-based bioprinting, *Int J Bioprint* 8 (2022) 424, <https://doi.org/10.18063/ijb.v8i1.424>.
- [22] S. Naghieh, X. Chen, Printability-A key issue in extrusion-based bioprinting, *J Pharm Anal* 11 (2021) 564–579, <https://doi.org/10.1016/j.jpaha.2021.02.001>.
- [23] A. Joshi, T. Kaur, N. Singh, 3D bioprinted alginate-silk-based smart cell-instructive scaffolds for dual differentiation of human mesenchymal stem cells, *ACS Appl. Bio Mater.* 5 (2022) 2870–2879, <https://doi.org/10.1021/acsabm.2c00251>.
- [24] A.V. Do, B. Khorsand, S.M. Geary, A.K. Salem, 3D printing of scaffolds for tissue regeneration applications, *Adv. Healthcare Mater.* 4 (2015) 1742–1762, <https://doi.org/10.1002/adhm.201500168>.
- [25] A. Erben, M. Horning, B. Hartmann, T. Becke, S.A. Eisler, A. Southan, S. Cranz, O. Hayden, N. Kneidinger, M. Konigshoff, et al., Precision 3D-printed cell scaffolds mimicking native tissue composition and mechanics, *Adv. Healthcare Mater.* 9 (2020) e2000918, <https://doi.org/10.1002/adhm.202000918>.
- [26] S.C. Gasoto, B. Schneider Jr., J.A.P. Setti, Study of the pulse of peristaltic pumps for use in 3D extrusion bioprinting, *ACS Omega* 7 (2022) 24091–24101, <https://doi.org/10.1021/acsomega.1c07093>.
- [27] K. Flegeau, A. Puiggali-Jou, M. Zenobi-Wong, Cartilage tissue engineering by extrusion bioprinting utilizing porous hyaluronic acid microgel bioinks, *Biofabrication* 14 (2022), <https://doi.org/10.1088/1758-5090/ac6b58>.
- [28] B.A. Frost, B.P. Sutliff, P. Thayer, M.J. Bortner, E.J. Foster, Gradient poly(ethylene glycol) diacrylate and cellulose nanocrystals tissue engineering composite scaffolds via extrusion bioprinting, *Front. Bioeng. Biotechnol.* 7 (2019) 280, <https://doi.org/10.3389/fbioe.2019.00280>.
- [29] A. Malekpour, X. Chen, Printability and cell viability in extrusion-based bioprinting from experimental, computational, and machine learning views, *J. Funct. Biomater.* 13 (2022), <https://doi.org/10.3390/jfb13020040>.
- [30] I.T. Ozbolat, M. Hospodiuk, Current advances and future perspectives in extrusion-based bioprinting, *Biomaterials* 76 (2016) 321–343, <https://doi.org/10.1016/j.biomaterials.2015.10.076>.
- [31] N. Chen, K. Zhu, Y.S. Zhang, S. Yan, T. Pan, M. Abudupataer, G. Yu, M.F. Alam, L. Wang, X. Sun, et al., Hydrogel bioink with multilayered interfaces improves dispersibility of encapsulated cells in extrusion bioprinting, *ACS Appl. Mater. Interfaces* 11 (2019) 30585–30595, <https://doi.org/10.1021/acsami.9b09782>.
- [32] P. Zhuang, W.L. Ng, J. An, C.K. Chua, L.P. Tan, Layer-by-layer ultraviolet assisted extrusion-based (UAE) bioprinting of hydrogel constructs with high aspect ratio for soft tissue engineering applications, *PLoS One* 14 (2019) e0216776, <https://doi.org/10.1371/journal.pone.0216776>.
- [33] H. Lee, J.J. Yoo, H.W. Kang, D.W. Cho, Investigation of thermal degradation with extrusion-based dispensing modules for 3D bioprinting technology, *Biofabrication* 8 (2016) 015011, <https://doi.org/10.1088/1758-5090/8/1/015011>.
- [34] K.K. Moncal, V. Ozbolat, P. Datta, D.N. Heo, I.T. Ozbolat, Thermally-controlled extrusion-based bioprinting of collagen, *J. Mater. Sci. Mater. Med.* 30 (2019) 55, <https://doi.org/10.1007/s10856-019-6258-2>.
- [35] M. Kuzucu, G. Vera, M. Beaumont, S. Fischer, P. Wei, V.P. Shastri, A. Forget, Extrusion-based 3D bioprinting of gradients of stiffness, cell density, and immobilized peptide using thermogelling hydrogels, *ACS Biomater. Sci. Eng.* 7 (2021) 2192–2197, <https://doi.org/10.1021/acsbomaterials.1c00183>.
- [36] A. Negro, T. Cherbuin, M.P. Lutolf, 3D inkjet printing of complex, cell-laden hydrogel structures, *Sci. Rep.* 8 (2018) 17099, <https://doi.org/10.1038/s41598-018-35504-2>.
- [37] I. Angelopoulos, M.C. Allenby, M. Lim, M. Zamorano, Engineering inkjet bioprinting processes toward translational therapies, *Biotechnol. Bioeng.* 117 (2020) 272–284, <https://doi.org/10.1002/bit.27176>.
- [38] C. Xu, W. Chai, Y. Huang, R.R. Markwald, Scaffold-free inkjet printing of three-dimensional zigzag cellular tubes, *Biotechnol. Bioeng.* 109 (2012) 3152–3160, <https://doi.org/10.1002/bit.24591>.
- [39] M.L. Bedell, A.L. Torres, K.J. Hogan, Z. Wang, B. Wang, A.J. Melchiorri, K.J. Grande-Allen, A.G. Mikos, Human gelatin-based composite hydrogels for osteochondral tissue engineering and their adaptation into bioinks for extrusion, inkjet, and digital light processing bioprinting, *Biofabrication* 14 (2022), <https://doi.org/10.1088/1758-5090/ac8768>.
- [40] A. Dufour, X.B. Gallostra, C. O’Keeffe, K. Eichholz, S. Von Eeuw, O. Garcia, D.J. Kelly, Integrating melt electrowriting and inkjet bioprinting for engineering structurally organized articular cartilage, *Biomaterials* 283 (2022) 121405, <https://doi.org/10.1016/j.biomaterials.2022.121405>.
- [41] J. Fernández-Pradas, M. Colina, P. Serra, J. Dominguez, J. Morenza, Laser-induced forward transfer of biomolecules, *Thin Solid Films* 453 (2004) 27–30.
- [42] R. Devillard, E. Pages, M.M. Correa, V. Keriquel, M. Remy, J. Kalisky, M. Ali, B. Guillotin, F. Guillemot, Cell patterning by laser-assisted bioprinting, *Methods Cell Biol.* 119 (2014) 159–174, <https://doi.org/10.1016/B978-0-12-416742-1.00009-3>.
- [43] O. Kerouedan, J.M. Bourget, M. Remy, S. Crauste-Manciet, J. Kalisky, S. Catros, N.B. Thebaud, R. Devillard, Micropatterning of endothelial cells to create a capillary-like network with defined architecture by laser-assisted bioprinting, *J. Mater. Sci. Mater. Med.* 30 (2019) 28, <https://doi.org/10.1007/s10856-019-6230-1>.
- [44] N. Touya, M. Devun, C. Handschin, S. Casenave, N. Ahmed Omar, A. Gaubert, N. Dusserre, H. De Oliveira, O. Kerouedan, R. Devillard, vivocharacterization of a novel tricalcium silicate-based ink for bone regeneration using laser-assisted bioprinting, *Biofabrication* 14 (2022), <https://doi.org/10.1088/1758-5090/ac584b>.
- [45] O. Kerouedan, D. Hakobyan, M. Remy, S. Ziane, N. Dusserre, J.C. Fricain, S. Delmond, N.B. Thebaud, R. Devillard, In situ prevascularization designed by laser-assisted bioprinting: effect on bone regeneration, *Biofabrication* 11 (2019) 045002, <https://doi.org/10.1088/1758-5090/ab2620>.
- [46] D. Hakobyan, O. Kerouedan, M. Remy, N. Dusserre, C. Medina, R. Devillard, J.C. Fricain, H. Oliveira, Laser-assisted bioprinting for bone repair, *Methods Mol. Biol.* 2140 (2020) 135–144, [https://doi.org/10.1007/978-1-0716-0520-2\\_8](https://doi.org/10.1007/978-1-0716-0520-2_8).
- [47] H.-Q. Xu, J.-C. Liu, Z.-Y. Zhang, C.-X. Xu, A review on cell damage, viability, and functionality during 3D bioprinting, *Military Medical Research* 9 (2022) 70, <https://doi.org/10.1186/s40779-022-00429-5>.
- [48] Z. Wang, H. Kumar, Z. Tian, X. Jin, J.F. Holzman, F. Menard, K. Kim, Visible light photoinitiation of cell-adhesive gelatin methacryloyl hydrogels for Stereolithography 3D bioprinting, *ACS Appl. Mater. Interfaces* 10 (2018) 26859–26869, <https://doi.org/10.1021/acsami.8b06607>.
- [49] N. Bhattacharjee, C. Parra-Cabrera, Y.T. Kim, A.P. Kuo, A. Folch, Desktop-stereolithography 3D-printing of a poly(dimethylsiloxane)-based material with sylgard-184 properties, *Adv Mater* 30 (2018) e1800001, <https://doi.org/10.1002/adma.201800001>.
- [50] S.S. Mahdavi, M.J. Abdekhoodaie, H. Kumar, S. Mashayekhan, A. Baradaran-Rafii, K. Kim, Stereolithography 3D bioprinting method for fabrication of human corneal stroma equivalent, *Ann. Biomed. Eng.* 48 (2020) 1955–1970, <https://doi.org/10.1007/s10439-020-02537-6>.
- [51] X. Neng, S. Guohong, S. Yuling, X. Yuanjing, W. Hao, F. Haiyang, D. Kerong, W. Jinwu, C. Qixin, Research progress of robot technology in in situ 3D bioprinting, *Int J Bioprint* 8 (2022) 614, <https://doi.org/10.18063/ijb.v8i4.614>.

- [52] V. Keriquel, F. Guillemot, I. Arnault, B. Guillotin, S. Miraux, J. Amédée, J.C. Fricain, S. Catros, In vivo bioprinting for computer- and robotic-assisted medical intervention: preliminary study in mice, *Biofabrication* 2 (2010) 014101, <https://doi.org/10.1088/1758-5082/2/1/014101>.
- [53] N. Hakimi, R. Cheng, L. Leng, M. Sotoudehfar, P.Q. Ba, N. Bakhtyar, S. Amini-Nik, M.G. Jeschke, A. Günther, Handheld skin printer: in situ formation of planar biomaterials and tissues, *Lab Chip* 18 (2018) 1440–1451, <https://doi.org/10.1039/c7lc01236e>.
- [54] J.H. Galarrraga, M.Y. Kwon, J.A. Burdick, 3D bioprinting via an in situ crosslinking technique towards engineering cartilage tissue, *Sci. Rep.* 9 (2019) 19987, <https://doi.org/10.1038/s41598-019-56117-3>.
- [55] D.F. Duarte Campos, S. Zhang, F. Kreimendahl, M. Köpf, H. Fischer, M. Vogt, A. Blaeser, C. Apel, M. Esteves-Oliveira, Hand-held bioprinting for de novo vascular formation applicable to dental pulp regeneration, *Connect. Tissue Res.* 61 (2020) 205–215, <https://doi.org/10.1080/03080207.2019.1640217>.
- [56] J.L. Hoehne, R. Carlström, J. Dernorwsek, P.C. Cristovam, H.L. Bachiega, S.I. Abensur, P. Schor, Piezoelectric 3D bioprinting for ophthalmological applications: process development and viability analysis of the technology, *Biomed Phys Eng Express* 6 (2020) 035021, <https://doi.org/10.1088/2057-1976/ab7bf9>.
- [57] H. Chen, Z. Wu, Z. Gong, Y. Xia, J. Li, L. Du, Y. Zhang, X. Gao, Z. Fan, H. Hu, et al., Acoustic bioprinting of patient-derived organoids for predicting cancer therapy responses, *Adv. Healthcare Mater.* 11 (2022) e2102784, <https://doi.org/10.1002/adhm.202102784>.
- [58] F. Safir, N. Vu, L.F. Tadesse, K. Firouzi, N. Banaei, S.S. Jeffrey, A.A.E. Saleh, B.P.T. Khuri-Yakub, J.A. Dionne, Combining acoustic bioprinting with AI-assisted Raman spectroscopy for high-throughput identification of bacteria in blood, *Nano Lett.* 23 (2023) 2065–2073, <https://doi.org/10.1021/acs.nanolett.2c03015>.
- [59] S. Jentsch, R. Nasehi, C. Kuckelkorn, B. Gundert, S. Aveic, H. Fischer, Multiscale 3D bioprinting by nozzle-free acoustic droplet ejection, *Small Methods* 5 (2021) e2000971, <https://doi.org/10.1002/smt.202000971>.
- [60] D.A. Bowser, M.J. Moore, Biofabrication of neural microphysiological systems using magnetic spheroid bioprinting, *Biofabrication* 12 (2019) 015002, <https://doi.org/10.1088/1758-5090/ab41b4>.
- [61] C. Adine, K.K. Ng, S. Rungarunlert, G.R. Souza, J.N. Ferreira, Engineering innervated secretory epithelial organoids by magnetic three-dimensional bioprinting for stimulating epithelial growth in salivary glands, *Biomaterials* 180 (2018) 52–66, <https://doi.org/10.1016/j.biomaterials.2018.06.011>.
- [62] B. Schmiege, S. Gretzinger, S. Schuhmann, G. Guthausen, J. Hubbuch, Magnetic resonance imaging as a tool for quality control in extrusion-based bioprinting, *Biotechnol. J.* 17 (2022) e2100336, <https://doi.org/10.1002/biot.202100336>.
- [63] A. Kasimu, H. Zhu, Z. Meng, Z. Qiu, Y. Wang, D. Li, J. He, Development of electro-conductive composite bioinks for electrohydrodynamic bioprinting with microscale resolution, *Adv Biol (Weinh)* (2023) e2300056, <https://doi.org/10.1002/adbi.202300056>.
- [64] J. He, B. Zhang, Z. Li, M. Mao, J. Li, K. Han, D. Li, High-resolution electrohydrodynamic bioprinting: a new biofabrication strategy for biomimetic micro/nanoscale architectures and living tissue constructs, *Biofabrication* 12 (2020) 042002, <https://doi.org/10.1088/1758-5090/aba1fa>.
- [65] B. Mahendiran, S. Muthusamy, S. Sampath, S.N. Jaisankar, K.C. Papat, R. Selvakumar, G.S. Krishnakumar, Recent trends in natural polysaccharide based bioinks for multiscale 3D printing in tissue regeneration: a review, *Int. J. Biol. Macromol.* 183 (2021) 564–588, <https://doi.org/10.1016/j.ijbiomac.2021.04.179>.
- [66] R. Li, Y. Zhao, Z. Zheng, Y. Liu, S. Song, L. Song, J. Ren, J. Dong, P. Wang, Bioinks adapted for in situ bioprinting scenarios of defect sites: a review, *RSC Adv.* 13 (2023) 7153–7167, <https://doi.org/10.1039/d2ra07037e>.
- [67] C.F. Marques, G.S. Diogo, S. Pina, J.M. Oliveira, T.H. Silva, R.L. Reis, Collagen-based bioinks for hard tissue engineering applications: a comprehensive review, *J. Mater. Sci. Mater. Med.* 30 (2019) 32, <https://doi.org/10.1007/s10856-019-6234-x>.
- [68] S. Heid, A.R. Boccaccini, Advancing bioinks for 3D bioprinting using reactive fillers: a review, *Acta Biomater.* 113 (2020) 1–22, <https://doi.org/10.1016/j.actbio.2020.06.040>.
- [69] K. Zhou, Y. Sun, J. Yang, H. Mao, Z. Gu, Hydrogels for 3D embedded bioprinting: a focused review on bioinks and support baths, *J. Mater. Chem. B* 10 (2022) 1897–1907, <https://doi.org/10.1039/d1tb02554f>.
- [70] S. Swaminathan, Q. Hamid, W. Sun, A.M. Clyne, Bioprinting of 3D breast epithelial spheroids for human cancer models, *Biofabrication* 11 (2019) 025003, <https://doi.org/10.1088/1758-5090/aaef49>.
- [71] X. Zhang, Y. Liu, Q. Zuo, Q. Wang, Z. Li, K. Yan, T. Yuan, Y. Zhang, K. Shen, R. Xie, W. Fan, 3D bioprinting of biomimetic bilayered scaffold consisting of decellularized extracellular matrix and silk fibroin for osteochondral repair, *Int J Bioprint* 7 (2021) 401, <https://doi.org/10.18063/ijb.v7i4.401>.
- [72] B.P. Oropeza, J.R. Adams, M.E. Furth, J. Chessa, T. Boland, Bioprinting of decellularized porcine cardiac tissue for large-scale aortic models, *Front. Bioeng. Biotechnol.* 10 (2022) 855186, <https://doi.org/10.3389/fbioe.2022.855186>.
- [73] X. Cui, J. Li, Y. Hartanto, M. Durham, J. Tang, H. Zhang, G. Hooper, K. Lim, T. Woodfield, Advances in extrusion 3D bioprinting: a focus on multicomponent hydrogel-based bioinks, *Adv. Healthcare Mater.* 9 (2020) e1901648, <https://doi.org/10.1002/adhm.201901648>.
- [74] R. Xiong, Z. Zhang, W. Chai, D.B. Chrisey, Y. Huang, Study of gelatin as an effective energy absorbing layer for laser bioprinting, *Biofabrication* 9 (2017) 024103, <https://doi.org/10.1088/1758-5090/aa74f2>.
- [75] H. Zhao, J. Xu, E. Zhang, R. Qi, Y. Huang, F. Lv, L. Liu, Q. Gu, S. Wang, 3D bioprinting of polythiophene materials for promoting stem cell proliferation in a nutritionally deficient environment, *ACS Appl. Mater. Interfaces* 13 (2021) 25759–25770, <https://doi.org/10.1021/acsmi.1c04967>.
- [76] F. Garcia-Villen, A. Gueembe, M.R. Jose, T. Zuniga, S. Ruiz-Alonso, L. Saenz-Del-Burgo, M.I. Jesus, I.R. Jose, J.L. Pedraz, Characterization and assessment of new fibrillar collagen inks and bioinks for 3D printing and bioprinting, *Int J Bioprint* 9 (2023) 712, <https://doi.org/10.18063/ijb.712>.
- [77] K. Guo, H. Wang, S. Li, P. Chang, C. He, Q. Sun, X. Zheng, Bioprinting of light-crosslinkable neutral-dissolved collagen to build implantable connective tissue with programmable cellular orientation, *Biofabrication* 15 (2023), <https://doi.org/10.1088/1758-5090/acc760>.
- [78] A. Dravid, A. McCaughey-Chapman, B. Raos, S.J. O'Carroll, B. Connor, D. Svirskis, Development of agarose-gelatin bioinks for extrusion-based bioprinting and cell encapsulation, *Biomed Mater* 17 (2022), <https://doi.org/10.1088/1748-605X/ac759f>.
- [79] Y. Ma, Y. Wang, D. Chen, T. Su, Q. Chang, W. Huang, F. Lu, 3D bioprinting of a gradient stiffened gelatin-alginate hydrogel with adipose-derived stem cells for full-thickness skin regeneration, *J. Mater. Chem. B* 11 (2023) 2989–3000, <https://doi.org/10.1039/d2tb02200a>.
- [80] A. Moro, S. Samanta, L. Honkamaki, V.K. Rangasami, P. Puustola, M. Kauppila, S. Narkilahti, S. Miettinen, O. Oommen, H. Skottman, Hyaluronic acid based next generation bioink for 3D bioprinting of human stem cell derived corneal stromal model with innervation, *Biofabrication* 15 (2022), <https://doi.org/10.1088/1758-5090/acab34>.
- [81] L.K. Shopperly, J. Spinnen, J.P. Kruger, M. Endres, M. Sittinger, T. Lam, L. Kloke, T. Dehne, Blends of gelatin and hyaluronic acid stratified by stereolithographic bioprinting approximate cartilaginous matrix gradients, *J. Biomed. Mater. Res. B Appl. Biomater.* 110 (2022) 2310–2322, <https://doi.org/10.1002/jbm.b.35079>.
- [82] M.A. Gwak, S.J. Lee, D. Lee, S.A. Park, W.H. Park, Highly gallol-substituted, rapidly self-crosslinkable, and robust chitosan hydrogel for 3D bioprinting, *Int. J. Biol. Macromol.* 227 (2023) 493–504, <https://doi.org/10.1016/j.ijbiomac.2022.12.124>.
- [83] F. Mohabatpour, X. Duan, Z. Yazdanpanah, X.L. Tabil, L. Lobanova, N. Zhu, S. Papagerakis, X. Chen, P. Papagerakis, Bioprinting of alginate-carboxymethyl chitosan scaffolds for enamel tissue engineering in vitro, *Biofabrication* 15 (2022), <https://doi.org/10.1088/1758-5090/acab35>.
- [84] L. Yueqi, X. Jie, S. Ya, F. Huan, L. Jiaqi, L. Siyao, C. Yuen Yee, N. Yi, L. Wenfang, P. Bo, S. Kedong, A biocompatible double-crosslinked gelatin/sodium alginate/dopamine/quaternized chitosan hydrogel for wound dressings based on 3D bioprinting technology, *Int J Bioprint* 9 (2023) 689, <https://doi.org/10.18063/ijb.v9i1.689>.
- [85] L. Jia, Y. Hua, J. Zeng, W. Liu, D. Wang, G. Zhou, X. Liu, H. Jiang, Bioprinting and regeneration of auricular cartilage using a bioactive bioink based on microporous photocrosslinkable acellular cartilage matrix, *Bioact. Mater.* 16 (2022) 66–81, <https://doi.org/10.1016/j.bioactmat.2022.02.032>.
- [86] R. Jin, Y. Cui, H. Chen, Z. Zhang, T. Weng, S. Xia, M. Yu, W. Zhang, J. Shao, M. Yang, et al., Three-dimensional bioprinting of a full-thickness functional skin model using acellular dermal matrix and gelatin methacrylamide bioink, *Acta Biomater.* 131 (2021) 248–261, <https://doi.org/10.1016/j.actbio.2021.07.012>.
- [87] N. Ashammakhi, S. Ahadian, C. Xu, H. Montazerian, H. Ko, R. Nasiri, N. Barros, A. Khademhosseini, Bioinks and bioprinting technologies to make heterogeneous and biomimetic tissue constructs, *Mater Today Bio* 1 (2019) 100008, <https://doi.org/10.1016/j.mtbio.2019.100008>.
- [88] M.D. Sarker, S. Naghieh, N.K. Sharma, L. Ning, X. Chen, Bioprinting of vascularized tissue scaffolds: influence of biopolymer, cells, growth factors, and gene delivery, *J. Healthc Eng* 2019 (2019) 9156921, <https://doi.org/10.1155/2019/9156921>.



- [89] F.E. Freeman, P. Pitacco, L.H.A. van Dommelen, J. Nulty, D.C. Browe, J.Y. Shin, E. Alsberg, D.J. Kelly, 3D bioprinting spatiotemporally defined patterns of growth factors to tightly control tissue regeneration, *Sci. Adv.* 6 (2020) eabb5093, <https://doi.org/10.1126/sciadv.abb5093>.
- [90] Y.J. Lee, M.C. Park, D.H. Park, H.M. Hahn, S.M. Kim, L.J. Lee, Effectiveness of acellular dermal matrix on autologous split-thickness skin graft in treatment of deep tissue defect: esthetic subjective and objective evaluation, *Aesthetic Plast. Surg.* 41 (2017) 1049–1057, <https://doi.org/10.1007/s00266-017-0891-2>.
- [91] P.H. Liem, N. Morimoto, R. Ito, K. Kawai, S. Suzuki, Autologous skin reconstruction by combining epidermis and acellular dermal matrix tissue derived from the skin of giant congenital melanocytic nevi, *J. Artif. Organs* 16 (2013) 332–342, <https://doi.org/10.1007/s10047-013-0708-2>.
- [92] B. Wang, T. Qinglai, Q. Yang, M. Li, S. Zeng, X. Yang, Z. Xiao, X. Tong, L. Lei, S. Li, Functional acellular matrix for tissue repair, *Mater Today Bio* 18 (2023) 100530, <https://doi.org/10.1016/j.mtbio.2022.100530>.
- [93] L. Muthukrishnan, Imminent antimicrobial bioink deploying cellulose, alginate, EPS and synthetic polymers for 3D bioprinting of tissue constructs, *Carbohydr. Polym.* 260 (2021) 117774, <https://doi.org/10.1016/j.carbpol.2021.117774>.
- [94] K. Zhou, M. Feng, H. Mao, Z. Gu, Photoclick polysaccharide-based bioinks with an extended biofabrication window for 3D embedded bioprinting, *Biomater. Sci.* 10 (2022) 4479–4491, <https://doi.org/10.1039/d2bm00632d>.
- [95] W. Arab, S. Rauf, O. Al-Harbi, C.A.E. Hauser, Novel ultrashort self-assembling peptide bioinks for 3D culture of muscle myoblast cells, *Int J Bioprint* 4 (2018) 129, <https://doi.org/10.18063/IJB.v4i2.129>.
- [96] J.P. Temple, D.L. Hutton, B.P. Hung, P.Y. Huri, C.A. Cook, R. Kondragunta, X. Jia, W.L. Grayson, Engineering anatomically shaped vascularized bone grafts with hASCs and 3D-printed PCL scaffolds, *J. Biomed. Mater. Res.* 102 (2014) 4317–4325, <https://doi.org/10.1002/jbm.a.35107>.
- [97] S. Hassanajili, A. Karami-Pour, A. Oryan, T. Taleai-Khozani, Preparation and characterization of PLA/PCL/HA composite scaffolds using indirect 3D printing for bone tissue engineering, *Mater. Sci. Eng., C* 104 (2019) 109960, <https://doi.org/10.1016/j.msec.2019.109960>.
- [98] K. Li, D. Wang, K. Zhao, K. Song, J. Liang, Electrohydrodynamic jet 3D printing of PCL/PVP composite scaffold for cell culture, *Talanta* 211 (2020) 120750, <https://doi.org/10.1016/j.talanta.2020.120750>.
- [99] J.L. Perry, K.G. Reuter, M.P. Kai, K.P. Herlihy, S.W. Jones, J.C. Luft, M. Napier, J.E. Bear, J.M. DeSimone, PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics, *Nano Lett.* 12 (2012) 5304–5310, <https://doi.org/10.1021/nl302638g>.
- [100] T.A. Brown, M.P. Galicia, G.W. Thiemann, S.T. Belt, D.J. Yurkowski, M.G. Dyck, High contributions of sea ice derived carbon in polar bear (*Ursus maritimus*) tissue, *PLoS One* 13 (2018) e0191631, <https://doi.org/10.1371/journal.pone.0191631>.
- [101] S. Naderi, A. Esmaili, Fabrication and characterization of 3D printing scaffold technology by extract oils from plant and its applications in the cardiovascular blood, *Sci. Rep.* 11 (2021) 24409, <https://doi.org/10.1038/s41598-021-03951-z>.
- [102] T. Guo, T.R. Holzberg, C.G. Lim, F. Gao, A. Gargava, J.E. Trachtenberg, A.G. Mikos, J.P. Fisher, 3D printing PLGA: a quantitative examination of the effects of polymer composition and printing parameters on print resolution, *Biofabrication* 9 (2017) 024101, <https://doi.org/10.1088/1758-5090/aa6370>.
- [103] T. Guo, C. Lim, M. Noshin, J.P. Ringel, J.P. Fisher, 3D printing bioactive PLGA scaffolds using DMSO as a removable solvent, *Bioprinting* 10 (2018), <https://doi.org/10.1016/j.bprint.2018.e00038>.
- [104] R.K. Pirlo, P. Wu, J. Liu, B. Ringeisen, PLGA/hydrogel biopapers as a stackable substrate for printing HUVEC networks via BioLP, *Biotechnol. Bioeng.* 109 (2012) 262–273, <https://doi.org/10.1002/bit.23295>.
- [105] P. Chen, L. Cui, G. Chen, T. You, W. Li, J. Zuo, C. Wang, W. Zhang, C. Jiang, The application of BMP-12-overexpressing mesenchymal stem cells loaded 3D-printed PLGA scaffolds in rabbit rotator cuff repair, *Int. J. Biol. Macromol.* 138 (2019) 79–88, <https://doi.org/10.1016/j.ijbiomac.2019.07.041>.
- [106] J. Kim, Characterization of biocompatibility of functional bioinks for 3D bioprinting, *Bioengineering (Basel)* 10 (2023), <https://doi.org/10.3390/bioengineering10040457>.
- [107] A.S. J. S. Velayudhan, A.K. Pr, Biocompatibility evaluation of antioxidant cocktail loaded gelatin methacrylamide as bioink for extrusion-based 3D bioprinting, *Biomed Mater* 18 (2023), <https://doi.org/10.1088/1748-605X/acd82f>.
- [108] W. Lim, S.Y. Shin, J.M. Cha, H. Bae, Optimization of polysaccharide hydrocolloid for the development of bioink with high printability/biocompatibility for coextrusion 3D bioprinting, *Polymers* 13 (2021), <https://doi.org/10.3390/polym13111773>.
- [109] B. Mahadik, R. Margolis, S. McLoughlin, A. Melchiorri, S.J. Lee, J. Yoo, A. Atala, A.G. Mikos, J.P. Fisher, An open-source bioink database for microextrusion 3D printing, *Biofabrication* 15 (2022), <https://doi.org/10.1088/1758-5090/ac933a>.
- [110] Y. Sun, K. Yu, J. Nie, M. Sun, J. Fu, H. Wang, Y. He, Modeling the printability of photocuring and strength adjustable hydrogel bioink during projection-based 3D bioprinting, *Biofabrication* 13 (2021), <https://doi.org/10.1088/1758-5090/aba413>.
- [111] Z. Galliger, C.D. Vogt, H.R. Helms, A. Panoskalis-Mortari, Extracellular matrix nanoparticles improve GelMA bioink resolution for 3D bioprinting at ambient temperature, *Macromol. Mater. Eng.* 307 (2022), <https://doi.org/10.1002/mame.202200196>.
- [112] A. Kostenko, C.J. Connon, S. Swioklo, Storable cell-laden alginate based bioinks for 3D biofabrication, *Bioengineering (Basel)* 10 (2022), <https://doi.org/10.3390/bioengineering10010023>.
- [113] L. Somasekhar, N.D. Huynh, A. Vecheck, V. Kishore, C.A. Bashur, K. Mitra, Three-dimensional printing of cell-laden microporous constructs using blended bioinks, *J. Biomed. Mater. Res.* 110 (2022) 535–546, <https://doi.org/10.1002/jbm.a.37303>.
- [114] Z. Wu, J. Liu, J. Lin, L. Lu, J. Tian, L. Li, C. Zhou, Novel digital light processing printing strategy using a collagen-based bioink with prospective cross-linker procyanidins, *Biomacromolecules* 23 (2022) 240–252, <https://doi.org/10.1021/acs.biomac.1c01244>.
- [115] M. Houmar, Q. Fu, E. Saiz, A.P. Tomsia, Sol-gel method to fabricate CaP scaffolds by robocasting for tissue engineering, *J. Mater. Sci. Mater. Med.* 23 (2012) 921–930, <https://doi.org/10.1007/s10856-012-4561-2>.
- [116] T. Cameron, E. Naseri, B. MacCallum, A. Ahmadi, Development of a disposable single-nozzle printhead for 3D bioprinting of continuous multi-material constructs, *Micromachines* 11 (2020), <https://doi.org/10.3390/mi11050459>.
- [117] Z. Deng, J. Chen, B. Lin, J. Li, H. Wang, D. Wang, L. Pang, X. Zeng, H. Wang, Y. Zhang, A novel 3D printed bioactive scaffolds with enhanced osteogenic inspired by ancient Chinese medicine HYSA for bone repair, *Exp. Cell Res.* 394 (2020) 112139, <https://doi.org/10.1016/j.yexcr.2020.112139>.
- [118] B. Sanz, A. Albillos Sanchez, B. Tangey, K. Gilmore, Z. Yue, X. Liu, G. Wallace, Light cross-linkable marine collagen for coaxial printing of a 3D model of neuromuscular junction formation, *Biomedicines* 9 (2020), <https://doi.org/10.3390/biomedicines9010016>.
- [119] V. Lemarteleur, M. Peycelon, J.L. Sablayrolles, P. Plaisance, A. El-Ghoneimi, P.F. Ceccaldi, Realization of open software chain for 3D modeling and printing of organs in simulation centers: example of renal pelvis reconstruction, *J. Surg. Educ.* 78 (2021) 232–244, <https://doi.org/10.1016/j.jsurg.2020.06.035>.
- [120] F.V. Sbrana, R. Pinos, F. Barboglio, D. Ribezzi, F. Scagnoli, L. Scarfo, I.N. Redwan, H. Martinez, S. Fare, P. Ghia, C. Scielzo, 3D bioprinting allows the establishment of long-term 3D culture model for chronic lymphocytic leukemia cells, *Front. Immunol.* 12 (2021) 639572, <https://doi.org/10.3389/fimmu.2021.639572>.
- [121] F.B. Albrecht, F.F. Schmidt, A.C. Volz, P.J. Kluger, Bioprinting of 3D adipose tissue models using a GelMA-bioink with human mature adipocytes or human adipose-sterem stem cells, *Gels* 8 (2022), <https://doi.org/10.3390/gels8100611>.
- [122] A.K. Amler, P.H. Dinkelborg, D. Schlauch, J. Spinnen, S. Stich, R. Lauster, M. Sittinger, S. Nahles, M. Heiland, L. Kloke, et al., Comparison of the translational potential of human mesenchymal progenitor cells from different bone entities for autologous 3D bioprinted bone grafts, *Int. J. Mol. Sci.* 22 (2021), <https://doi.org/10.3390/ijms22020796>.
- [123] A.R. Abdel Fattah, E. Meleca, S. Mishriki, A. Lelic, F. Geng, R.P. Sahu, S. Ghosh, I.K. Puri, In situ 3D label-free contactless bioprinting of cells through diamagnetophoresis, *ACS Biomater. Sci. Eng.* 2 (2016) 2133–2138, <https://doi.org/10.1021/acsbiomaterials.6b00614>.
- [124] C.C. Clark, K.M. Yoo, H. Sivakumar, K. Strumpf, A.W. Laxton, S.B. Tatter, R.E. Strowd, A. Skardal, Immersion bioprinting of hyaluronan and collagen bioink-supported 3D patient-derived brain tumor organoids, *Biomed Mater* 18 (2022), <https://doi.org/10.1088/1748-605X/aca05d>.
- [125] P.A. Mollica, E.N. Booth-Creech, J.A. Reid, M. Zamponi, S.M. Sullivan, X.L. Palmer, P.C. Sachs, R.D. Bruno, 3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels, *Acta Biomater.* 95 (2019) 201–213, <https://doi.org/10.1016/j.actbio.2019.06.017>.
- [126] M. Tang, Q. Xie, R.C. Gimple, Z. Zhong, T. Tam, J. Tian, R.L. Kidwell, Q. Wu, B.C. Prager, Z. Qiu, et al., Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions, *Cell Res.* 30 (2020) 833–853, <https://doi.org/10.1038/s41422-020-0338-1>.



- [127] T. Distler, A.A. Solisito, D. Schneidereit, O. Friedrich, R. Detsch, A.R. Boccaccini, 3D printed oxidized alginate-gelatin bioink provides guidance for C2C12 muscle precursor cell orientation and differentiation via shear stress during bioprinting, *Biofabrication* 12 (2020) 045005, <https://doi.org/10.1088/1758-5090/ab98e4>.
- [128] T. Fan, S. Wang, Z. Jiang, S. Ji, W. Cao, W. Liu, Y. Ji, Y. Li, N. Shyh-Chang, Q. Gu, Controllable assembly of skeletal muscle-like bundles through 3D bioprinting, *Biofabrication* 14 (2021), <https://doi.org/10.1088/1758-5090/ac3aca>.
- [129] B. Byambaa, N. Annabi, K. Yue, G. Trujillo-de Santiago, M.M. Alvarez, W. Jia, M. Kazemzadeh-Narbat, S.R. Shin, A. Tamayol, A. Khademhosseini, Bioprinted osteogenic and vasculogenic patterns for engineering 3D bone tissue, *Adv. Healthcare Mater.* 6 (2017), <https://doi.org/10.1002/adhm.201700015>.
- [130] M.B. Immohr, F. Dos Santos Adrego, H.L. Teichert, V. Schmidt, Y. Sugimura, S. Bauer, M. Barth, A. Lichtenberg, P. Akhyari, 3D-bioprinting of Aortic Valve Interstitial Cells: Impact of Hydrogel and Printing Parameters on Cell Viability, vol. 18, *Biomedical materials*, Bristol, England, 2022, <https://doi.org/10.1088/1748-605X/ac9f91>.
- [131] L. Lian, C. Zhou, G. Tang, M. Xie, Z. Wang, Z. Luo, J. Japo, D. Wang, J. Zhou, M. Wang, et al., Uniaxial and coaxial vertical embedded extrusion bioprinting, *Adv. Healthcare Mater.* 11 (2022) e2102411, <https://doi.org/10.1002/adhm.202102411>.
- [132] P.-J. Tebon, B. Wang, A.L. Markowitz, A. Davarifar, B.L. Tsai, P. Krawczuk, A.E. Gonzalez, S. Sartini, G.F. Murray, H.T.L. Nguyen, et al., Drug screening at single-organoid resolution via bioprinting and interferometry, *Nat. Commun.* 14 (2023) 3168, <https://doi.org/10.1038/s41467-023-38832-8>.
- [133] T. Xu, H. Kincaid, A. Atala, J.J. Yoo, High-throughput production of single-cell microparticles using an inkjet printing technology, *J. Manuf. Sci. Eng.* 130 (2008), <https://doi.org/10.1115/1.2903064>.
- [134] C. Norotte, F.S. Marga, L.E. Niklason, G. Forgacs, Scaffold-free vascular tissue engineering using bioprinting, *Biomaterials* 30 (2009) 5910–5917, <https://doi.org/10.1016/j.biomaterials.2009.06.034>.
- [135] E.A. Sokoot, E. Arkan, M. Khazaei, P. Moradipour, A novel 3D-electrospun nanofibers-scaffold grafted with Royal Jelly: improve hydrophilicity of the nanofibers-scaffold and proliferation of HUVEC cell line, *Cell Tissue Bank.* 24 (2023) 329–340, <https://doi.org/10.1007/s10561-022-10035-3>.
- [136] H. Yang, L. Sun, Y. Pang, D. Hu, H. Xu, S. Mao, W. Peng, Y. Wang, Y. Xu, Y.C. Zheng, et al., Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure, *Gut* 70 (2021) 567–574, <https://doi.org/10.1136/gutjnl-2019-319960>.
- [137] J. Lee, D.N. Foster, W.G. Botjje, H.M. Jang, Y.G. Chandra, L.E. Gentles, B.W. Kong, Establishment of an immortal chicken embryo liver-derived cell line, *Poult Sci.* 92 (2013) 1604–1612, <https://doi.org/10.3382/ps.2012-02582>.
- [138] N. Muraqi, M. Yamada, H. Doki, R. Nakai, K. Komeda, D. Goto, N. Kawabe, K. Matsuoka, M. Matsushima, T. Kawabe, et al., Resistance to mutant KRAS(V12)-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line, *Exp. Cell Res.* 414 (2022) 113053, <https://doi.org/10.1016/j.yexcr.2022.113053>.
- [139] J. Harwood, A. Tachibana, M. Meuth, Multiple dispersed spontaneous mutations: a novel pathway of mutation in a malignant human cell line, *Mol. Cell Biol.* 11 (1991) 3163–3170, <https://doi.org/10.1128/mcb.11.6.3163-3170.1991>.
- [140] Z. Salatanpour, B. Johari, A. Alizadeh, M. Lotfinia, A.K. Majidzadeh, B. Nikbin, M. Kadivar, Enrichment of cancer stem-like cells by the induction of epithelial-mesenchymal transition using lentiviral vector carrying E-cadherin shRNA in HT29 cell line, *J. Cell. Physiol.* 234 (2019) 22935–22946, <https://doi.org/10.1002/jcp.28855>.
- [141] G. Byrne, S.M. O'Rourke, D.L. Alexander, B. Yu, R.C. Doran, M. Wright, Q. Chen, P. Azadi, P.W. Berman, CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation, *PLoS Biol.* 16 (2018) e2005817, <https://doi.org/10.1371/journal.pbio.2005817>.
- [142] A. Mitani, T. Kobayashi, Y. Hayashi, N. Matsushita, S. Matsushita, S. Nakao, N. Takahira, A. Shiraishi, Y. Ohashi, Characterization of doxycycline-dependent inducible Simian Virus 40 large T antigen immortalized human conjunctival epithelial cell line, *PLoS One* 14 (2019) e0222454, <https://doi.org/10.1371/journal.pone.0222454>.
- [143] W.L. Kaufman, I. Kocman, V. Agrawal, H.P. Rahn, D. Besser, M. Gossen, Homogeneity and persistence of transgene expression by omitting antibiotic selection in cell line isolation, *Nucleic Acids Res.* 36 (2008) e111, <https://doi.org/10.1093/nar/gkn508>.
- [144] M.-J. Jeon, B.R. Haugen, Preclinical models of follicular cell-derived thyroid cancer: an overview from cancer cell lines to mouse models, *Endocrinol Metab (Seoul)* 37 (2022) 830–838, <https://doi.org/10.3803/EnM.2022.1636>.
- [145] J. Teishima, S. Inoue, T. Hayashi, K. Mita, Y. Hasegawa, M. Kato, M. Kajiwara, M. Shigeta, S. Maruyama, H. Moriyama, et al., Impact of the systemic immune-inflammation index for the prediction of prognosis and modification of the risk model in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors, *Can Urol Assoc J* 14 (2020) E582–E587, <https://doi.org/10.5489/auaj.6413>.
- [146] Y. Wu, X. Chen, W. Bao, X. Hong, C. Li, J. Lu, D. Zhang, A. Zhu, Effect of humantenine on mRNA m6A modification and expression in human colon cancer cell line HCT116, *Genes* 13 (2022), <https://doi.org/10.3390/genes13050781>.
- [147] L. Ouyang, R. Yao, X. Chen, J. Na, W. Sun, 3D printing of HEK 293FT cell-laden hydrogel into macroporous constructs with high cell viability and normal biological functions, *Biofabrication* 7 (2015) 015010, <https://doi.org/10.1088/1758-5090/7/1/015010>.
- [148] HUV-EC-C [HUVEC] - CRL-1730 | ATCC. <https://www.atcc.org/products/crl-1730>.
- [149] M. Cuvellier, F. Ezan, H. Oliveira, S. Rose, J.C. Fricain, S. Langouet, V. Legagneux, G. Baffet, 3D culture of HepaRG cells in GelMA and its application to bioprinting of a multicellular hepatic model, *Biomaterials* 269 (2021) 120611, <https://doi.org/10.1016/j.biomaterials.2020.120611>.
- [150] A. Fritschen, M. Acedo Mestre, S. Scholpp, A. Blaeser, Influence of the physico-chemical bioink composition on the printability and cell biological properties in 3D-bioprinting of a liver tumor cell line, *Front. Bioeng. Biotechnol.* 11 (2023) 1093101, <https://doi.org/10.3389/fbioe.2023.1093101>.
- [151] E.P. Tracy, B.C. Gettler, J.S. Zakhari, R.J. Schwartz, S.K. Williams, R.K. Birla, 3D bioprinting the cardiac purkinje system using human adipogenic mesenchymal stem cell derived purkinje cells, *Cardiovasc Eng Technol* 11 (2020) 587–604, <https://doi.org/10.1007/s13239-020-00478-8>.
- [152] B.E. Grottkau, Z. Hui, Y. Pang, A novel 3D bioprinter using direct-volumetric drop-on-demand technology for fabricating micro-tissues and drug-delivery, *Int. J. Mol. Sci.* 21 (2020), <https://doi.org/10.3390/ijms21103482>.
- [153] Y. Li, X. Jiang, L. Li, Z.N. Chen, G. Gao, R. Yao, W. Sun, 3D printing human induced pluripotent stem cells with novel hydroxypropyl chitin bioink: scalable expansion and uniform aggregation, *Biofabrication* 10 (2018) 044101, <https://doi.org/10.1088/1758-5090/aacfc3>.
- [154] M.A. Skylar-Scott, S.G.M. Uzel, L.L. Nam, J.H. Ahrens, R.L. Truby, S. Damaraju, J.A. Lewis, Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channels, *Sci. Adv.* 5 (2019) eaaw2459, <https://doi.org/10.1126/sciadv.aaw2459>.
- [155] Y. Han, M. King, E. Tikhomirov, P. Barasa, C.D.S. Souza, J. Lindh, D. Baltrikiene, L. Ferraiuolo, M. Azzouz, M.R. Gullo, E.N. Kozlova, Towards 3D bioprinted spinal cord organoids, *Int. J. Mol. Sci.* 23 (2022), <https://doi.org/10.3390/ijms23105788>.
- [156] N. Noor, A. Shapira, R. Edri, I. Gal, L. Wertheim, T. Dvir, 3D printing of personalized thick and perfusable cardiac patches and hearts, *Adv. Sci.* 6 (2019) 1900344, <https://doi.org/10.1002/advs.201900344>.
- [157] W. Ji, B. Hou, W. Lin, L. Wang, W. Zheng, W. Li, J. Zheng, X. Wen, P. He, 3D Bioprinting a human iPSC-derived MSC-loaded scaffold for repair of the uterine endometrium, *Acta Biomater.* 116 (2020) 268–284, <https://doi.org/10.1016/j.actbio.2020.09.012>.
- [158] E. Abelseth, L. Abelseth, L. De la Vega, S.T. Beyer, S.J. Wadsworth, S.M. Willerth, 3D printing of neural tissues derived from human induced pluripotent stem cells using a fibrin-based bioink, *ACS Biomater. Sci. Eng.* 5 (2019) 234–243, <https://doi.org/10.1021/acsbomaterials.8b01235>.
- [159] Y. Fang, Y. Guo, B. Wu, Z. Liu, M. Ye, Y. Xu, M. Ji, L. Chen, B. Lu, K. Nie, et al., Expanding embedded 3D bioprinting capability for engineering complex organs with freeform vascular networks, *Adv Mater* 35 (2023) e2205082, <https://doi.org/10.1002/adma.202205082>.
- [160] M. Ghafarzadeh, P. Namdari, M. Tarhani, F. Tarhani, A review of application of stem cell therapy in the management of congenital heart disease, *J. Matern. Fetal Neonatal Med.* 33 (2020) 1607–1615, <https://doi.org/10.1080/14767058.2018.1520829>.
- [161] N. Jia, J. Chong, L. Sun, Application of stem cell biology in treating neurodegenerative diseases, *Int. J. Neurosci.* 132 (2022) 815–825, <https://doi.org/10.1080/00207454.2020.1840376>.
- [162] Y.C. Tao, E.Q. Chen, Clinical application of stem cell in patients with end-stage liver disease: progress and challenges, *Ann. Transl. Med.* 8 (2020) 564, <https://doi.org/10.21037/atm.2020.03.153>.
- [163] S. Masuda, S. Miyagawa, S. Fukushima, N. Sougawa, E. Ito, M. Takeda, A. Saito, Y. Sawa, Emerging innovation towards safety in the clinical application of ESCs and iPSCs, *Nat. Rev. Cardiol.* 11 (2014) 553–554, <https://doi.org/10.1038/nrcardio.2014.9-c1>.

- [164] M.T. Zhao, H. Chen, Q. Liu, N.Y. Shao, N. Sayed, H.T. Wo, J.Z. Zhang, S.G. Ong, C. Liu, Y. Kim, et al., Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs, *Proc Natl Acad Sci U S A* 114 (2017) E11111–E11120, <https://doi.org/10.1073/pnas.1708991114>.
- [165] C. Yu, X. Ma, W. Zhu, P. Wang, K.L. Miller, J. Stupin, A. Koroleva-Maharajh, A. Hairabedian, S. Chen, Scanningless and continuous 3D bioprinting of human tissues with decellularized extracellular matrix, *Biomaterials* 194 (2019) 1–13, <https://doi.org/10.1016/j.biomaterials.2018.12.009>.
- [166] M. Hirano, Y. Huang, D. Vela Jarquin, R.L. De la Garza Hernandez, Y.A. Jodati, E. Luna Ceron, L.E. Garcia-Rivera, S.R. Shin, 3D bioprinted human iPSC-derived somatosensory constructs with functional and highly purified sensory neuron networks, *Biofabrication* 13 (2021), <https://doi.org/10.1088/1758-5090/abff11>.
- [167] L. Ouyang, R. Yao, Y. Zhao, W. Sun, Effect of bioink properties on printability and cell viability for 3D bioplotting of embryonic stem cells, *Biofabrication* 8 (2016) 035020, <https://doi.org/10.1088/1758-5090/8/3/035020>.
- [168] M.J. Song, R. Quinn, E. Nguyen, C. Hampton, R. Sharma, T.S. Park, C. Koster, T. Voss, C. Tristan, C. Weber, et al., Bioprinted 3D outer retina barrier uncovers RPE-dependent choroidal phenotype in advanced macular degeneration, *Nat. Methods* 20 (2023) 149–161, <https://doi.org/10.1038/s41592-022-01701-1>.
- [169] M.A. Skylar-Scott, J.Y. Huang, A. Lu, A.H.M. Ng, T. Duenki, S. Liu, L.L. Nam, S. Damaraju, G.M. Church, J.A. Lewis, Orthogonally induced differentiation of stem cells for the programmatic patterning of vascularized organoids and bioprinted tissues, *Nat. Biomed. Eng.* 6 (2022) 449–462, <https://doi.org/10.1038/s41551-022-00856-8>.
- [170] R. Rikhtegar, M. Pezeshkian, S. Dolati, N. Safaie, A. Afrasiabi Rad, M. Mahdipour, M. Nouri, A.R. Jodati, M. Yousefi, Stem cells as therapy for heart disease: iPSCs, ESCs, and skeletal myoblasts, *Biomed. Pharmacother.* 109 (2019) 304–313, <https://doi.org/10.1016/j.biopha.2018.10.065>.
- [171] T. Tsugata, N. Nikoh, T. Kin, I. Saitoh, Y. Noguchi, H. Ueki, M. Watanabe, A.M. James Shapiro, H. Noguchi, Potential factors for the differentiation of ESCs/iPSCs into insulin-producing cells, *Cell Med.* 7 (2015) 83–93, <https://doi.org/10.3727/215517914X685178>.
- [172] Y. Li, C. Park, L. Vellon, X. Li, iPSCs: from bench to clinical bed, *Stem Cells Int* 2016 (2016) 8367587, <https://doi.org/10.1155/2016/8367587>.
- [173] S. Pandey, M. Jirasko, J. Lochman, A. Chvatal, M. Chottova Dvorakova, R. Kucera, iPSCs in neurodegenerative disorders: a unique platform for clinical research and personalized medicine, *J Pers Med* 12 (2022), <https://doi.org/10.3390/jpm12091485>.
- [174] N. Sayed, C. Liu, M. Ameen, F. Himmati, J.Z. Zhang, S. Khanamiri, J.R. Moonen, A. Wnorowski, L. Cheng, J.W. Rhee, et al., Clinical trial in a dish using iPSCs shows lovastatin improves endothelial dysfunction and cellular cross-talk in LMNA cardiomyopathy, *Sci. Transl. Med.* 12 (2020), <https://doi.org/10.1126/scitranslmed.aax9276>.
- [175] M. Takeda, E. Ito, K. Minami, A. Harada, N. Mochizuki-Oda, Y. Sawa, S. Miyagawa, Elimination of residual undifferentiated induced pluripotent stem cells (iPSCs) using irradiation for safe clinical applications of iPSC-derived cardiomyocytes, *Biochem. Biophys. Res. Commun.* 574 (2021) 91–96, <https://doi.org/10.1016/j.bbrc.2021.08.065>.
- [176] G. Boix-Lemonche, R.M. Nagymihaly, E.M. Niemi, N. Josifovska, S. Johansen, M.C. Moe, H. Scholz, G. Petrovski, Intra-Corneal implantation of 3D bioprinted scaffolds containing mesenchymal stromal cells using femtosecond-laser-assisted intrastromal keratoplasty, *Macromol. Biosci.* (2023) e2200422, <https://doi.org/10.1002/mabi.202200422>.
- [177] Y. Huang, S. Tsubota, N. Nishio, Y. Takahashi, K. Kadomatsu, Combination of tumor necrosis factor-alpha and epidermal growth factor induces the adrenergic-to-mesenchymal transdifferentiation in SH-SY5Y neuroblastoma cells, *Cancer Sci.* 112 (2021) 715–724, <https://doi.org/10.1111/cas.14760>.
- [178] Y.D. Cho, K.H. Kim, Y.M. Lee, Y. Ku, Y.J. Seol, Dental-derived cells for regenerative medicine: stem cells, cell reprogramming, and transdifferentiation, *J Periodontol Implant Sci* 52 (2022) 437–454, <https://doi.org/10.5051/jpis.2103760188>.
- [179] S. Gong, H. Shao, X. Cai, J. Zhu, Astrocyte-derived neuronal transdifferentiation as a therapy for ischemic stroke: advances and challenges, *Brain Sci.* 12 (2022), <https://doi.org/10.3390/brainsci12091175>.
- [180] C.A. Greene, C.R. Green, T. Sherwin, Transdifferentiation of chondrocytes into neuron-like cells induced by neuronal lineage specifying growth factors, *Cell Biol. Int.* 39 (2015) 185–191, <https://doi.org/10.1002/cbin.10358>.
- [181] W.T. Wong, J.P. Cooke, Therapeutic transdifferentiation of human fibroblasts into endothelial cells using forced expression of lineage-specific transcription factors, *J. Tissue Eng.* 7 (2016) 2041731416628329, <https://doi.org/10.1177/2041731416628329>.
- [182] Z. Zhao, M. Xu, M. Wu, X. Tian, C. Zhang, X. Fu, Transdifferentiation of fibroblasts by defined factors, *Cell Reprogram* 17 (2015) 151–159, <https://doi.org/10.1089/cell.2014.0089>.
- [183] S. Zhu, H. Wang, S. Ding, Reprogramming fibroblasts toward cardiomyocytes, neural stem cells and hepatocytes by cell activation and signaling-directed lineage conversion, *Nat. Protoc.* 10 (2015) 959–973, <https://doi.org/10.1038/nprot.2015.059>.
- [184] P. Huang, L. Zhang, Y. Gao, Z. He, D. Yao, Z. Wu, J. Cen, X. Chen, C. Liu, Y. Hu, et al., Direct reprogramming of human fibroblasts to functional and expandable hepatocytes, *Cell Stem Cell* 14 (2014) 370–384, <https://doi.org/10.1016/j.stem.2014.01.003>.
- [185] Y. Wang, Q. Zheng, Z. Sun, C. Wang, J. Cen, X. Zhang, Y. Jin, B. Wu, T. Yan, Z. Wang, et al., Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes, *Cell Stem Cell* 30 (2023) 617–631, <https://doi.org/10.1016/j.stem.2023.03.013>, e618.
- [186] P. Huang, Z. He, S. Ji, H. Sun, D. Xiang, C. Liu, Y. Hu, X. Wang, L. Hui, Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors, *Nature* 475 (2011) 386–389, <https://doi.org/10.1038/nature10116>.
- [187] T.H. Lee, P.S. Liu, S.J. Wang, M.M. Tsai, V. Shanmugam, H.L. Hsieh, Bradykinin, as a reprogramming factor, induces transdifferentiation of brain astrocytes into neuron-like cells, *Biomedicines* 9 (2021), <https://doi.org/10.3390/biomedicines9080923>.
- [188] M. Takaishi, S. Sano, Transdifferentiation of melanoma cells by the reprogramming factors attenuates malignant nature in vitro and in vivo, *J. Invest. Dermatol.* 139 (2019) 254–257, <https://doi.org/10.1016/j.jid.2018.06.179>.
- [189] S. Chakraborty, J. Schneider, J.A. Boockvar, Transdifferentiation-induced neural stem cells for the treatment of malignant gliomas, *Neurosurgery* 79 (2016) N12–N13, <https://doi.org/10.1227/01.neu.0000499705.20596.5d>.
- [190] A. Cim, G.J. Sawyer, X. Zhang, H. Su, L. Collins, P. Jones, M. Antoniou, J.P. Reynes, H.J. Lipps, J.W. Fabre, In vivo studies on non-viral transdifferentiation of liver cells towards pancreatic beta cells, *J. Endocrinol.* 214 (2012) 277–288, <https://doi.org/10.1530/JOE-12-0033>.
- [191] Y. Yuan, C. Wang, X. Zhuang, S. Lin, M. Luo, W. Deng, J. Zhou, L. Liu, L. Mao, W. Peng, et al., PIM1 promotes hepatic conversion by suppressing reprogramming-induced ferroptosis and cell cycle arrest, *Nat. Commun.* 13 (2022) 5237, <https://doi.org/10.1038/s41467-022-32976-9>.
- [192] M. Rimann, E. Bono, H. Annaheim, M. Bleisch, U. Graf-Hausner, Standardized 3D bioprinting of soft tissue models with human primary cells, *J. Lab. Autom.* 21 (2016) 496–509, <https://doi.org/10.1177/2211068214567146>.
- [193] B. Vu, G.R. Souza, J. Dengjel, Scaffold-free 3D cell culture of primary skin fibroblasts induces profound changes of the matrisome, *Matrix Biol.* 11 (2021) 100066, <https://doi.org/10.1016/j.mbps.2021.100066>.
- [194] M. Cuvelier, S. Rose, F. Ezan, U. Jarry, H. de Oliveira, A. Bruyere, C. Drieu La Rochelle, V. Legagneux, S. Langouet, G. Baffet, term differentiation and functionality of three-dimensional bioprinted primary human hepatocytes: application for in vivo engraftment, *Biofabrication* 14 (2022), <https://doi.org/10.1088/1758-5090/ac7825>.
- [195] N. Rajendran, F. Deng, Y. Wang, O. Kenziar, J. Krishnan, T. Biswas, T. Parmely, N. Rohner, C. Zhao, Establishment, long-term maintenance, and characterization of primary liver cells from *Astyanax mexicanus*, *Curr Protoc* 3 (2023) e736, <https://doi.org/10.1002/cpz1.736>.
- [196] H.J. Chen, P. Miller, M.L. Shuler, A pumpless body-on-a-chip model using a primary culture of human intestinal cells and a 3D culture of liver cells, *Lab Chip* 18 (2018) 2036–2046, <https://doi.org/10.1039/c8lc00111a>.
- [197] K.H. Kim, J. Qiu, S. Kuang, Isolation, culture, and differentiation of primary myoblasts derived from muscle satellite cells, *Bio Protoc* 10 (2020) e3686, <https://doi.org/10.21769/BioProtoc.3686>.
- [198] K. Metzger, A. Tuchscherer, M.F. Palin, S. Ponsuksili, C. Kalbe, Establishment and validation of cell pools using primary muscle cells derived from satellite cells of pig skeletal muscle, *In Vitro Cell. Dev. Biol. Anim.* 56 (2020) 193–199, <https://doi.org/10.1007/s11626-019-00428-2>.
- [199] V. Tiran, J. Lindenmann, L. Brcic, E. Heitzer, S. Stanzer, N.G. Tabrizi-Wizsy, E. Stacher, H. Stoeger, H.H. Popper, M. Balic, N. Dandachi, Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition, *Sci. Rep.* 7 (2017) 10040, <https://doi.org/10.1038/s41598-017-09929-0>.

- [200] C. Ngan, A. Quigley, C. O'Connell, M. Kita, J. Bourke, G.G. Wallace, P. Choong, R.M.I. Kapsa, 3D bioprinting and differentiation of primary skeletal muscle progenitor cells, *Methods Mol. Biol.* 2140 (2020) 229–242, [https://doi.org/10.1007/978-1-0716-0520-2\\_15](https://doi.org/10.1007/978-1-0716-0520-2_15).
- [201] M.M. De Santis, H.N. Alsafadi, S. Tas, D.A. Bolukbas, S. Prithiviraj, I.A.N. Da Silva, M. Mittendorfer, C. Ota, J. Stegmayr, F. Daoud, et al., Extracellular-matrix-reinforced bioinks for 3D bioprinting human tissue, *Adv Mater* 33 (2021) e2005476, <https://doi.org/10.1002/adma.202005476>.
- [202] J. Zheng, Y. Liu, C. Hou, Z. Li, S. Yang, X. Liang, L. Zhou, J. Guo, J. Zhang, X. Huang, Ovary-derived decellularized extracellular matrix-based bioink for fabricating 3D primary ovarian cells-laden structures for mouse ovarian failure correction, *Int J Bioprint* 8 (2022) 597, <https://doi.org/10.18063/ijb.v8i3.597>.
- [203] C. McBeth, J. Lauer, M. Ottersbach, J. Campbell, A. Sharon, A.F. Sauer-Budge, 3D bioprinting of GelMA scaffolds triggers mineral deposition by primary human osteoblasts, *Biofabrication* 9 (2017) 015009, <https://doi.org/10.1088/1758-5090/aa53bd>.
- [204] D.F. Duarte Campos, M. Rohde, M. Ross, P. Anvari, A. Blaeser, M. Vogt, C. Panfil, G.H. Yam, J.S. Mehta, H. Fischer, et al., Corneal bioprinting utilizing collagen-based bioinks and primary human keratocytes, *J. Biomed. Mater. Res.* 107 (2019) 1945–1953, <https://doi.org/10.1002/jbm.a.36702>.
- [205] L. De Moor, S. Fernandez, C. Vercruyse, L. Tytgat, M. Asadian, N. De Geyter, S. Van Vlierberghe, P. Dubruel, H. Declercq, Hybrid bioprinting of chondrogenically induced human mesenchymal stem cell spheroids, *Front. Bioeng. Biotechnol.* 8 (2020) 484, <https://doi.org/10.3389/fbioe.2020.00484>.
- [206] X. Liu, X. Wang, L. Zhang, L. Sun, H. Wang, H. Zhao, Z. Zhang, W. Liu, Y. Huang, S. Ji, et al., 3D liver tissue model with branched vascular networks by multimaterial bioprinting, *Adv. Healthcare Mater.* 10 (2021) e2101405, <https://doi.org/10.1002/adhm.202101405>.
- [207] D. Wang, S. Maharjan, X. Kuang, Z. Wang, L.S. Mille, M. Tao, P. Yu, X. Cao, L. Lian, L. Lv, et al., Microfluidic bioprinting of tough hydrogel-based vascular conduits for functional blood vessels, *Sci. Adv.* 8 (2022) eabq6900, <https://doi.org/10.1126/sciadv.abq6900>.
- [208] Z.M. Jessop, A. Al-Sabah, N. Gao, S. Kyle, B. Thomas, N. Badiei, K. Hawkins, I.S. Whitaker, Printability of pulp derived crystal, fibril and blend nanocellulose-alginate bioinks for extrusion 3D bioprinting, *Biofabrication* 11 (2019) 045006, <https://doi.org/10.1088/1758-5090/ab0631>.
- [209] F. Xie, L. Sun, Y. Pang, G. Xu, B. Jin, H. Xu, X. Lu, Y. Xu, S. Du, Y. Wang, et al., Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine, *Biomaterials* 265 (2021) 120416, <https://doi.org/10.1016/j.biomaterials.2020.120416>.
- [210] L.R. Madden, T.V. Nguyen, S. Garcia-Mojica, V. Shah, A.V. Le, A. Peier, R. Visconti, E.M. Parker, S.C. Presnell, D.G. Nguyen, K.N. Retting, Bioprinted 3D primary human intestinal tissues model aspects of native physiology and ADME/tox functions, *iScience* 2 (2018) 156–167, <https://doi.org/10.1016/j.isci.2018.03.015>.
- [211] S. Agarwala, J.M. Lee, W.L. Ng, M. Layani, W.Y. Yeong, S. Magdassi, A novel 3D bioprinted flexible and biocompatible hydrogel bioelectronic platform, *Biosens. Bioelectron.* 102 (2018) 365–371, <https://doi.org/10.1016/j.bios.2017.11.039>.
- [212] X. Zhou, H. Cui, M. Nowicki, S. Miao, S.J. Lee, F. Masood, B.T. Harris, L.G. Zhang, Three-Dimensional-bioprinted dopamine-based matrix for promoting neural regeneration, *ACS Appl. Mater. Interfaces* 10 (2018) 8993–9001, <https://doi.org/10.1021/acsami.7b18197>.
- [213] G.D.M. Jeffries, S. Xu, T. Lobovkina, V. Kirejev, F. Tusseau, C. Gyllensten, A.K. Singh, P. Karila, L. Moll, O. Orwar, 3D micro-organisation printing of mammalian cells to generate biological tissues, *Sci. Rep.* 10 (2020) 19529, <https://doi.org/10.1038/s41598-020-74191-w>.
- [214] L. Karamchand, A. Wagner, S.B. Alam, M. Kulka, Fabrication of a crystalline nanocellulose embedded agarose biomaterial ink for bone marrow-derived mast cell culture, *J. Vis. Exp.* (2021), <https://doi.org/10.3791/62519>.
- [215] C. Scognamiglio, A. Soloperto, G. Ruocco, G. Cidonio, Bioprinting stem cells: building physiological tissues one cell at a time, *Am J Physiol Cell Physiol* 319 (2020) C465–C480, <https://doi.org/10.1152/ajpcell.00124.2020>.
- [216] B.D. Coffin, A.R. Hudson, A. Lee, A.W. Feinberg, FRESH 3D bioprinting a ventricle-like cardiac construct using human stem cell-derived cardiomyocytes, *Methods Mol. Biol.* 2485 (2022) 71–85, [https://doi.org/10.1007/978-1-0716-2261-2\\_5](https://doi.org/10.1007/978-1-0716-2261-2_5).
- [217] F. Yu, D. Choudhury, Microfluidic bioprinting for organ-on-a-chip models, *Drug Discov. Today* 24 (2019) 1248–1257, <https://doi.org/10.1016/j.drudis.2019.03.025>.
- [218] L. Shao, Q. Gao, C. Xie, J. Fu, M. Xiang, Y. He, Synchronous 3D bioprinting of large-scale cell-laden constructs with nutrient networks, *Adv. Healthcare Mater.* 9 (2020) e1901142, <https://doi.org/10.1002/adhm.201901142>.
- [219] A. Elalouf, Immune response against the biomaterials used in 3D bioprinting of organs, *Transpl. Immunol.* 69 (2021) 101446, <https://doi.org/10.1016/j.trim.2021.101446>.
- [220] S. Mehrotra, R.D. Singh, A. Bandyopadhyay, G. Janani, S. Dey, B.B. Mandal, Engineering microsphere-loaded non-mulberry silk-based 3D bioprinted vascularized cardiac patches with oxygen-releasing and immunomodulatory potential, *ACS Appl. Mater. Interfaces* 13 (2021) 50744–50759, <https://doi.org/10.1021/acsami.1c14118>.
- [221] P.R. Turner, E. Murray, C.J. McAdam, M.A. McConnell, J.D. Cabral, Peptide chitosan/dextran core/shell vascularized 3D constructs for wound healing, *ACS Appl. Mater. Interfaces* 12 (2020) 32328–32339, <https://doi.org/10.1021/acsami.0c07212>.
- [222] K. Chen, E. Jiang, X. Wei, Y. Xia, Z. Wu, Z. Gong, Z. Shang, S. Guo, The acoustic droplet printing of functional tumor microenvironments, *Lab Chip* 21 (2021) 1604–1612, <https://doi.org/10.1039/d1lc00003a>.
- [223] H. Herrada-Manchon, L. Celada, D. Rodriguez-Gonzalez, M. Alejandro Fernandez, E. Aguilar, M.D. Chiara, Three-dimensional bioprinted cancer models: a powerful platform for investigating tunneling nanotube-like cell structures in complex microenvironments, *Mater. Sci. Eng., C* 128 (2021) 112357, <https://doi.org/10.1016/j.msec.2021.112357>.